Document:

Exhibit
10.23

  

CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED

BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND
(II) IS THE TYPE

THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

 

Execution
Version

 

 

 

 

 

AGREEMENT
AND PLAN OF MERGER

 

by
and among

 

CELULARITY
INC.,

 

CLARITY
ACQUISITION CORP,

 

CLARITY
ACQUISITION II LLC,

 

ANTHROGENESIS
CORPORATION

 

and

 

CELGENE
CORPORATION

 

 

Dated:
July 1, 2017

 

 

 

 

 

     

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
 BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE
 THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

    

 

TABLE
OF CONTENTS

 

 

	 	 	 	 	Page
	 	 	 	 	 
	Article
    I	DEFINITIONS;
    INTERPRETATION	 	2
	Section 1.1	 	Definitions	 	2
	Section 1.2	 	Interpretation
    and Rules of Construction	 	14
	Article
    II	THE
    MERGERS; CLOSING	 	15
	Section 2.1	 	Merger
    One	 	15
	Section 2.2	 	Merger
    Two	 	15
	Section 2.3	 	The
    Closing	 	16
	Section 2.4	 	Issuance
    of the Buyer Shares; Closing Deliverables	 	16
	Section 2.5	 	Withholding	 	17
	Section 2.6	 	Tax
    Treatment	 	17
	Article
    III	REPRESENTATIONS
    AND WARRANTIES OF THE COMPANY	 	17
	Section 3.1	 	Organization,
    Qualification and Organizational Power	 	18
	Section 3.2	 	Authorization;
    Binding Effect	 	18
	Section 3.3	 	Approvals
    and Consents	 	18
	Section 3.4	 	Brokerage	 	19
	Section 3.5	 	Capitalization	 	19
	Section 3.6	 	Assets	 	19
	Section 3.7	 	Governmental
    Permits	 	19
	Section 3.8	 	Employees
    and Employment Matters	 	20
	Section 3.9	 	Real
    and Personal Property	 	21
	Section 3.10	 	No
    Violation, Litigation or Regulatory Action	 	21
	Section 3.11	 	Intellectual
    Property	 	22
	Section 3.12	 	Material
    Contracts	 	23
	Section 3.13	 	Taxes	 	24
	Section 3.14	 	Affiliate
    Transactions	 	24
	Article
    IV	REPRESENTATIONS
    AND WARRANTIES OF SELLER	 	25
	Section 4.1	 	Organization,
    Qualification and Organizational Power	 	25
	Section 4.2	 	Authorization;
    Binding Effect	 	25
	 	 	 	 	 

    i

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
 BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE
 THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

    

 

TABLE OF CONTENTS

(continued)

 

	 	 	 	 	Page
	 	 	 	 	 
	Section 4.3	 	Approvals
    and Consents	 	25
	Section 4.4	 	Brokerage	 	26
	Section 4.5	 	Investment
    Related Representations and Warranties	 	26
	Article V	REPRESENTATIONS AND WARRANTIES OF BUYER, MERGER SUB 1 AND MERGER SUB 2	 	27
	Section 5.1	 	Organization, Qualification and Organizational Power	 	27
	Section 5.2	 	Authorization; Binding Effect	 	27
	Section 5.3	 	Approvals and Consents	 	27
	Section 5.4	 	Brokerage	 	28
	Section 5.5	 	Capitalization	 	28
	Section 5.6	 	Financing	 	29
	Section 5.7	 	No Merger Sub Operations	 	29
	Section 5.8	 	Reorganization	 	29
	Article VI	COVENANTS	 	29
	Section 6.1	 	Consents; Regulatory Filings	 	29
	Section 6.2	 	Conduct of Business	 	31
	Section 6.3	 	Access and Certain Information	 	32
	Section 6.4	 	Insurance Matters	 	33
	Section 6.5	 	Cessation of Use of Seller’s Marks	 	33
	Section 6.6	 	Employee Matters	 	33
	Section 6.7	 	Public Announcements	 	34
	Section 6.8	 	Transaction Expenses	 	34
	Section 6.9	 	Further Assurances	 	34
	Section 6.10	 	Seller Assets; Surviving Entity Assets	 	35
	Section 6.11	 	Financing Activities	 	35
	Section 6.12	 	Buyer Acknowledgement	 	36
	Section 6.13	 	Transferred Intellectual Property Files	 	36
	Section 6.14	 	Transition Services Agreement	 	36
	 	 	 	 	 

    ii

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
 BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE
 THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

    

 

TABLE OF CONTENTS

(continued)

 

	 	 	 	 	Page
	 	 	 	 	 
	Article
    VII	CONDITIONS
    TO THE CLOSING	 	37
	Section 7.1	 	Conditions to Obligations of each of Buyer, Seller and the Company to Closing	 	37
	Section 7.2	 	Conditions to Buyer’s Obligation	 	37
	Section 7.3	 	Conditions to Seller’s and the Company’s Obligation	 	38
	Article
    VIII	TERMINATION	 	39
	Section 8.1	 	Termination	 	39
	Section 8.2	 	Effect of Termination	 	40
	Article
    IX	INDEMNIFICATION	 	40
	Section 9.1	 	Indemnification.	 	40
	Section 9.2	 	Procedures for Indemnification	 	41
	Section 9.3	 	Limitations on Indemnification	 	42
	Section 9.4	 	Effect of Knowledge	 	45
	Article
    X	TAX
    MATTERS	 	45
	Section 10.1	 	Tax Indemnity	 	45
	Section 10.2	 	Filing and Payment Responsibility	 	46
	Section 10.3	 	Tax Refunds	 	47
	Section 10.4	 	Audits	 	47
	Section 10.5	 	Cooperation	 	48
	Section 10.6	 	Coordination with Other Provisions	 	48
	Section 10.7	 	Transfer Taxes	 	48
	Section 10.8	 	Period of Limitation	 	48
	Section 10.9	 	Amended Returns	 	49
	Section 10.10	 	Loss and Tax Attribute Carrybacks	 	49
	Section 10.11	 	Closing Date Activities	 	49
	Section 10.12	 	Consolidated Group Tax Matters	 	49
	 	 	 	 	 

    iii

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
 BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE
 THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

    

 

TABLE OF CONTENTS

(continued)

 

	 	 	 	 	Page
	 	 	 	 	 
	Article
    XI	MISCELLANEOUS	 	49
	Section 11.1	 	Confidentiality	 	49
	Section 11.2	 	Consent to Amendments; Waiver	 	50
	Section 11.3	 	Entire Agreement	 	50
	Section 11.4	 	Successors and Assigns	 	50
	Section 11.5	 	Governing Law; Consent to Jurisdiction; Venue; Waiver of Jury Trial	 	50
	Section 11.6	 	Notices	 	51
	Section 11.7	 	Schedules; Disclosure Schedules	 	52
	Section 11.8	 	Counterparts	 	52
	Section 11.9	 	Severability	 	52
	Section 11.10	 	Time is of the Essence	 	52
	Section 11.11	 	No Third-Party Beneficiaries	 	52
	Section 11.12	 	No Strict Construction	 	52
	Section 11.13	 	No Set Off	 	52
	Section 11.14	 	Acknowledgement by Buyer	 	53
	Section 11.15	 	No Additional Representations	 	53
	 	 	 	 	 

    iv

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
 BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE
 THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

    

 

SCHEDULES

 

Schedule
1.1 – Other Transactions

 

Schedule
2.4(c)(ii) – Required Consents, Waivers or Approvals

 

Schedule
5.3(a) – Consents from, or Filings with, Governmental Entities

 

Schedule
5.5(a) – Capitalization of Buyer, Merger Sub 1 and Merger Sub 2

 

Schedule
5.5(b) – Rights to Acquire Equity Interests of Buyer

 

Schedule
6.12(d) – Excluded BCMA CAR-T Lab Equipment

 

 

EXHIBITS

 

Exhibit
A – License Agreement

 

Exhibit
B – CVR Agreement

 

Exhibit
C – Investor Rights Agreement

 

Exhibit
D – Voting Agreement

 

Exhibit
E – Investment Rights Agreement

 

Exhibit
F – Stock Purchase Agreement

 

    v

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
 BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE
 THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

    

 

AGREEMENT
AND PLAN OF MERGER

 

This
AGREEMENT AND PLAN OF MERGER (this “Agreement”) is made as of July 1, 2017 (the “Agreement
Date”), by and among Celgene Corporation, a Delaware corporation (“Seller”), Anthrogenesis
Corporation, a New Jersey corporation and a wholly owned subsidiary of Seller (the “Company”), Celularity
Inc., a Delaware corporation (“Buyer”), Clarity Acquisition Corp, a New Jersey corporation and a wholly
owned subsidiary of Buyer (“Merger Sub 1”), and Clarity Acquisition II LLC, a New Jersey limited liability
company and a wholly owned subsidiary of Buyer (“Merger Sub 2”).

 

WHEREAS,
Seller owns all of the issued and outstanding shares of common stock of the Company (the “Shares”);

 

WHEREAS,
the Parties intend that, upon the terms and subject to the conditions set forth in this Agreement, at the Closing, (a) Merger
Sub 1 be merged with and into the Company, with the Company continuing as the surviving entity (“Merger One”),
and (b) immediately following the consummation of Merger One, the Company be merged with and into Merger Sub 2, with Merger Sub
2 continuing as the surviving entity (“Merger Two” and, together with Merger One, the “Mergers”);

 

WHEREAS,
the respective boards of directors or equivalent governing bodies of each of Buyer, Merger Sub 1, Merger Sub 2 and the Company
have (a) determined that this Agreement and the transactions contemplated hereby, including the Mergers, are in the best interests
of their respective companies and respective equityholders, (b) authorized, approved and declared advisable this Agreement and
the transactions contemplated hereby, including the Mergers, and (c) recommended the adoption of this Agreement by their respective
equityholders in accordance with the New Jersey Business Corporation Act, as amended (the “NJBCA”),
as applicable;

 

WHEREAS,
for U.S. federal income tax purposes, the Mergers are intended to qualify as a “plan of reorganization”
within the meaning of Section 368(a) of the Code (as defined below);

 

WHEREAS,
each of (i) Buyer, in its capacity as the sole stockholder of Merger Sub 1 and the sole member of Merger Sub 2, and (ii) Seller,
in its capacity as the sole stockholder of the Company, has approved and declared advisable this Agreement and the respective
Mergers, upon the terms and subject to the conditions set forth in this Agreement; and

 

WHEREAS,
in furtherance of the foregoing, the Parties desire to enter into the Transaction Documents (as hereinafter defined).

 

NOW,
THEREFORE, in consideration of the premises and the representations, warranties, covenants and agreements contained in this Agreement,
and intending to be legally bound hereby, the Parties hereby agree as follows:

 

    1

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
 BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE
 THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

    

 

Article
I

DEFINITIONS; INTERPRETATION

 

Section
1.1 Definitions. For the purposes of this Agreement, the
following terms have the meanings set forth below:

 

“Action”
means any action, audit, claim, complaint, demand, hearing, litigation, mediation, proceeding, citation, summons, subpoena or
suit, whether civil, criminal, administrative or judicial commenced, brought, conducted or heard by or before, or otherwise involving,
any Governmental Entity.

 

“Affiliate”
means, as to any Person, any other Person who, directly or indirectly, controls, is controlled by, or is under common control
with, such Person. For purposes of this definition, the term “control” of a Person means (a) the power
to vote, directly or indirectly, fifty percent (50%) or more of the securities having ordinary voting power for the election of
directors of such Person or (b) the possession, directly or indirectly, of the power to direct or cause the direction of the management
and policies of such Person, whether through the ownership of voting securities, by Contract or otherwise, and the terms “controlled”
and “controlling” have meanings correlative thereto. For the avoidance of doubt, (x) prior to the Closing,
Buyer shall not be deemed to be an Affiliate of Seller or the Company, and neither Seller nor the Company shall be deemed to be
an Affiliate of Buyer, and (y) from and after the Closing, neither Buyer nor the Surviving Entity shall be deemed to be an Affiliate
of Seller, and Seller shall not be deemed to be an Affiliate of Buyer or the Surviving Entity.

 

“Antitrust
Law” means the Sherman Act, as amended, the Clayton Act, as amended, the HSR Act, the Federal Trade Commission Act,
as amended, any foreign competition Law, and all other foreign or domestic Laws, decrees, administrative and judicial doctrines
that are designed or intended to prohibit, restrict or regulate actions having the purpose or effect of monopolization, restraint
of trade or lessening of competition.

 

“BCMA
CAR-T Program” means any and all activities conducted by the Company, on behalf or in the name of Seller, directed
to the manufacture of BCMA-specific CAR T-cells pursuant to the June 3, 2015 Amended and Restated Master Collaboration Agreement
between Seller and bluebird bio, Inc., and/or pursuant to the December 15, 2014 Manufacturing and Clinical Supply Agreement between
Seller and bluebird bio, Inc., including all materials and Intellectual Property of any kind developed in the course of such activities.

 

“Business
Day” means any day excluding Saturday, Sunday and any day which is a legal holiday under the Laws of the State of
New Jersey, or is a day on which banking institutions located in New Jersey are authorized or required by Law or other governmental
action to close.

 

“Buyer
Fundamental Representations” means the representations and warranties of Buyer, Merger Sub 1 and Merger Sub 2 in
Section 5.1 (Organization, Qualification and Power), Section 5.2 (Authorization; Binding Effect),
Section 5.4 (Brokerage), Section 5.5 (Capitalization), and Section 5.6 (Financing).

 

    2

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
 BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE
 THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

    

 

“Buyer
Material Adverse Effect” means any event, change, development, effect, condition, occurrence or state of facts that
is materially adverse to the operations, financial condition or value of, or obligations in respect of, Buyer or that prevents
or materially delays the ability of Buyer to timely perform its obligations under, and to consummate the transactions contemplated
by, this Agreement.

 

“Buyer
Note” means that certain Promissory Note, dated October 31, 2016, issued by Buyer to Sorrento Therapeutics, Inc.,
as amended by Amendment No. 1, dated June 12, 2017.

 

“Buyer
Shares” means such number of shares of Buyer’s Series X Preferred Stock as is equal to fifteen percent (15%)
of the outstanding equity of Buyer on a fully diluted basis after giving effect to the issuance, or proposed issuance, of all
equity interests in connection with or contemplated by the Financing and the transactions described on Schedule 1.1.

 

“Buyer
Transaction Expenses” means, without duplication, (a) the aggregate third party legal, accounting, consulting, investment
banking, financial advisory, brokerage and other third party fees and expenses incurred by or on behalf of the Buyer, Merger Sub
1 or Merger Sub 2 in connection with this Agreement, the Transaction Documents and the Contemplated Transactions; and (b) all
fees and expenses associated with obtaining necessary or appropriate consents of any Governmental Entities pursuant to the HSR
Act or any other Antitrust Law in connection with the Contemplated Transactions.

 

“CAR-NK
Program” means activities conducted by the Company, for itself or on behalf of or in the name of Seller, relating
to certain chimeric antigen receptors, expression of the chimeric antigen receptors in natural killer (NK) cells, and NK cells
expressing the chimeric antigen receptors (“CAR NK Cells”), wherein such chimeric antigen receptors
are designed to function within NK cells and to target the NK cell expressing them to tumor targets, including all materials and
Intellectual Property of any kind developed in the course of such activities; provided, that, in no event shall the BCMA
CAR-T Program be deemed to be a CAR-NK Program. “CAR-NK Program” does not include PNK-007, unmodified NK cells, or
NK cells comprising a genetic modification other than expression of a chimeric antigen receptor, or any Intellectual Property
relating thereto.

 

“Closing
Buyer Share Price” means $4.8225 (as adjusted for any stock splits, reverse stock splits or similar events following
the Agreement Date and prior to the Closing).

 

“Code”
means the Internal Revenue Code of 1986, as amended.

 

“Commercialization”
means any and all activities related to the distribution, exploitation, marketing, promoting, offering for sale and selling of
a product, including advertising, educating, planning, obtaining, supporting and maintaining pricing and reimbursement approvals
and Regulatory Approvals, managing and responding to adverse events involving the product, pricing, price reporting, marketing,
promoting, detailing, storing, handling, shipping, distributing, importing, exporting, using, offering for sale, or selling a
product anywhere in the world. When used as a verb, “Commercialize” means to engage in Commercialization.

 

    3

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
 BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE
 THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

    

 

“Company
Intellectual Property” means all Intellectual Property owned by Company and used or held for use exclusively in
connection with Company Program Products.

 

“Company
Patent” means any Patent that is (a) owned by the Company and (b) Covers a Company Program Product.

 

“Company
Programs” means each of the following programs of the Company: (i) the PDA-001 program, (ii) the PDA-002 program,
(iii) the PNK-007 Program and (iv) the Genetically Modified NK Cell program originated by the Company.

 

“Company
Program Product” means any product containing or comprising (i) PDA-001, (ii) PDA-002, (iii) PNK-007, or (iv) the
Genetically Modified NK Cells, and any derivatives, parts, subparts, or progeny of any of the forgoing or any product based or
derived, in whole or in part, on any of the Company Programs as such Company Programs exist as of the Closing Date, whether such
product is Developed or Commercialized by the Company or any of its Affiliates, or any licensee, assignee or successor in interest
to any of them.

 

“Company
Registered Intellectual Property” means any Company Intellectual Property for which the Company has applied for
a registration in any country, including Patents, and patent applications, trademarks and trademark applications and copyright
and copyright applications.

 

“Contemplated
Transactions” means the transactions contemplated by this Agreement and the Transaction Documents.

 

“CVR
Agreement” means that certain Contingent Value Rights Agreement to be entered into by and between Buyer and Seller
in the form attached hereto as Exhibit B.

 

“Contract”
means any agreement, contract, license, obligation or commitment to which a party is bound or to which its assets or properties
are subject, whether oral or written, and any amendments and supplements thereto.

 

“Controlled”
when used in connection with any Intellectual Property, means the legal authority or right of a Person or any of its Affiliates
(whether by ownership or license) to grant the right to use an item or a license or sublicense of Intellectual Property rights
or to otherwise disclose proprietary or trade secret information without breach of terms of any agreement with a third party or
misappropriating the proprietary or trade secret or Know How of a third Person.

 

“Cover”
means, with reference to a Patent, that the Manufacture, use, sale, offer for sale or importation of a product, or practice of
a method, would infringe a Valid Claim of such Patent in the country in which such activity occurs without a license thereto.

 

“CTL”
means antigen-specific cytotoxic T lymphocytes generated by a process proprietary to the Company as of the Closing Date.

 

“CTL
Program” means all Company programs related to CTL, including, without limitation, TST-001; provided, that,
in no event shall the BCMA CAR-T Program be deemed to be a CTL Program.

 

    4

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
 BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE
 THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

    

 

“Debt”
means, with respect to any Person, all (a) indebtedness of such Person for borrowed money, whether short term or long term; (b)
indebtedness evidenced by notes, debentures, bonds or other similar instruments; (c) indebtedness issued or assumed for the deferred
purchase price of goods or services (but, in the case of Company, excluding accounts payable or accruals arising in the ordinary
course of business); (d) liabilities for the reimbursement of any obligor on any letter of credit or similar credit transaction
servicing liabilities of a Person or of a type described in clauses (a), (b) and (c) above and (e) below; (e) guarantees of liabilities
of the type referred to in clauses (a) through (d) of other Persons; and (f) all interest, fees and other expenses, including
prepayment penalties and other breakage fees, owed (or that would be owed upon prepayment) with respect to any of the indebtedness
described in clauses (a) through (e).

 

“Development”
means any and all activities related to developing a product, including non-clinical (including preclinical) and clinical research,
testing and development activities relating to the discovery and development of product candidates and submission of information
and applications to a Regulatory Authority, including toxicology, pharmacology, and other discovery, optimization, and preclinical
efforts, test method development and stability testing, manufacturing process development, formulation development, upscaling,
validation, delivery system development, quality assurance and quality control development, statistical analysis, managing and
responding to adverse events involving a product, clinical trials, other clinical studies (including pre- and post-Regulatory
Approval studies), and activities relating to obtaining Regulatory Approvals, but excluding Commercialization activities. When
used as a verb, “Develop” means to engage in Development.

 

“EMA”
means the European Medicines Agency, or any successor agency thereto.

 

“EMA
Regulatory Approval” means approval granted by the EMA, as evidenced by publication of approval by the EMA of an
MAA to market and sell a Company Program Product for a particular indication. For the avoidance of doubt, an “approval letter”
or similar communication published by the EMA shall not constitute approval for purposes of the foregoing.

 

“ERISA”
means the Employee Retirement Income Security Act of 1974, as amended.

 

“ERISA
Affiliate” of any entity means any other entity or any trade or business (whether or not incorporated) that, together
with such entity, would be treated as a single employer under Sections 414(b), (c), (m) or (o) of the Code or is under common
control with such entity under Section 4001(a)(14) or 4001(b)(1) of ERISA.

 

“Exploit”
means, collectively, Develop, have Developed, Manufacture, have Manufactured, Commercialize, have Commercialized, research, use,
and otherwise commercially exploit. “Exploitation” has a correlative meaning.

 

“FDA”
means the U.S. Food and Drug Administration, or any successor agency thereto.

 

“Fundamental
Representations” means the Seller Fundamental Representations and the Buyer Fundamental Representations.

 

    5

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
 BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE
 THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

    

 

“GAAP”
means United States generally accepted accounting principles as in effect from time to time, provided that, to the extent
that a Party adopts International Financial Reporting Standards (“IFRS”), then “GAAP”
means IFRS, consistently applied.

 

“Genetically
Modified NK Cell” means PNK-007 cells that comprise a genetic modification (for example, deletion, insertion, gene
silencing, expression of a non-native protein); provided, however, that, notwithstanding the foregoing, the term specifically
does not include or encompass NK cell expressing a chimeric receptor, including a chimeric antigen receptor.

 

“Governmental
Entity” means any nation or government, any foreign or domestic federal, state, county, municipal or other political
instrumentality, regulatory or administrative body or subdivision thereof and any foreign or domestic entity or body exercising
executive, legislative, judicial, regulatory, administrative or taxing functions of or pertaining to government, including any
court or tribunal.

 

“Governmental
Order” means any order, writ, judgment, injunction, decree, stipulation, determination or award entered by or with
any Governmental Entity.

 

“HSR
Act” means the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and the regulations promulgated
thereunder.

 

“Intellectual
Property” means, on a worldwide basis: (a) Patents and inventions (whether or not patentable); (b) trademarks, service
marks, logos, trade dress and trade names; (c) copyrights and design rights, whether registered or unregistered, and pending applications
to register the same, including in software; (d) Internet domain names and registrations thereof; and (e) Know-How.

 

“IRS”
means the United States Internal Revenue Service.

 

“Know-How”
means know-how, trade secrets, techniques, data, inventions, practices, methods, content of notebooks and other confidential or
proprietary technical, business, research, development and other similar information.

 

“Knowledge”
with respect to Seller or the Company means the knowledge of [***], and with respect to Buyer means the knowledge of [***], in
each case, including knowledge of such persons that would be acquired after reasonable inquiry.

 

“Law”
means any federal, national, supranational, state, provincial, local or administrative statute, law, ordinance, regulation, rule,
code, order, requirement or rule of law (including common law).

 

“License
Agreement” means that certain License Agreement to be entered by and between the Company and Seller in the form
attached hereto as Exhibit A.

 

“Licensed
Intellectual Property” means all of the Intellectual Property which exclusively relates to Company Program Products
and which is licensed to the Company pursuant to a licensing arrangement with a third party, including any Non-Customized Licensing
Software.

 

    6

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
 BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE
 THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

    

 

“Lien”
means any mortgage, pledge, lien, security interest or other encumbrance.

 

“Losses”
means, with respect to any Person, the amount of any liabilities, costs, damages, deficiencies, Taxes, penalties, fines, settlements,
judgments or other losses or expenses (including costs of investigation and defense and reasonable attorney and other professional
advisor and consulting fees and expenses) incurred by such Person.

 

“MAA”
means an application, including a biologics license application (BLA) or a new drug application (NDA), for the authorization to
market a pharmaceutical product in any country or group of countries, as defined under applicable Laws and regulations and filed
with the applicable Regulatory Authority of such country or group of countries, and all additions, supplements, extensions and
modifications thereto.

 

“Manufacturing”
means all activities directed to sourcing of necessary raw materials, producing, processing, packaging, quality assurance testing
and release of a drug candidate. When used as a verb, “Manufacture” means to engage in Manufacturing.

 

“Material
Adverse Effect” means any event, change, development, effect, condition, occurrence or state of facts that is or
would reasonably be expected to (1) be materially adverse to the operations, financial condition or value of the Transferred Business,
taken as a whole, or (2) be materially adverse to, prevent or materially delay the ability of Seller or the Company to carry out
its obligations under this Agreement, any Transaction Document or to consummate the Contemplated Transactions; provided, that
none of the following, either alone or in combination, shall be considered in determining whether there has been a “Material
Adverse Effect” or a breach of a representation, warranty, covenant or agreement that is qualified by the term “Material
Adverse Effect”: (a) events, circumstances, changes (including legal and regulatory changes) or effects that generally affect
the industries or segments thereof in which the Company operates, (b) general business, economic or political conditions (or changes
therein) or events, circumstances, changes or effects affecting the securities markets generally, (c) changes arising from the
consummation of the transactions contemplated by, or the announcement of the execution of, or any action taken pursuant to or
in furtherance of, this Agreement or at the request of or by Buyer or any of its Affiliates or Representatives, (d) any reduction
in the price of services or products offered by the Company in response to the reduction in price of comparable services or products
offered by a competitor, (e) any event, circumstance, change or effect caused by acts of terrorism or war (whether or not declared)
occurring after the Agreement Date, (f) changes or modifications in GAAP or applicable Law or interpretations thereof, and (g)
the failure in and of itself (as distinguished from any change or effect giving rise to or contributing to such failure) by the
Company to meet any estimates, expectations, projections or budgets; and provided further, that, any event, circumstance,
change or condition in each case of clause (a), (b) and (f), will be considered in determining whether there has been a “Material
Adverse Effect” to the extent it materially and adversely disproportionately affects the Transferred Business, taken as
a whole, relative to other businesses operating in the industries or segments thereof in which the Transferred Business operates.

 

    7

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
 BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE
 THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

    

 

“Material
Contract” means each of the following Contracts in effect as of the Agreement Date to which the Company is a party
or by which the Company is bound:

 

(a) each
Contract involving actual or potential payments to or from the Company in excess of $100,000 in the aggregate in any 12-month
period or during the remaining term thereof;

 

(b) each
Contract providing for “earn-outs,” “performance guarantees” or other similar contingent payments by the
Company;

 

(c) each
Contract between or among the Company, on the one hand, and the Seller or any of its Affiliates, on the other hand;

 

(d) each
Contract (i) providing for annual compensation payments greater than $100,000, (ii) providing for severance, termination or “golden
parachute” payments or stay or retention bonuses or other similar payments upon the consummation of the Contemplated Transactions
or (iii) with any individual who resides or works for or on behalf of the Company outside the United States;

 

(e) each
Contract providing for the lease or sublease by or to the Company (as lessor, sublessor, lessee or sublessee) of any real property;

 

(f) each
Contract imposing any material restriction on the right or ability of the Company to operate the Transferred Business, including
to (i) compete with, or solicit the services or employment of, any other Person; (ii) sell any product or other asset, or perform
any services, anywhere in the world; (iii) acquire any product or other asset or any services from any other Person; or (iv) develop,
use, sell or license any Company Intellectual Property;

 

(g) each
Contract where the Company grants material exclusivity rights or “most favored nations” status to the counterparty
thereof;

 

(h) each
Contract concerning a partnership, joint venture, teaming arrangement or involving the sharing of profits or expenses to which
the Company is a party or is otherwise bound;

 

(i) each
Contract pursuant to which the Company is committed to make a capital expenditure or to purchase a capital asset after the Agreement
Date in excess of $100,000;

 

(j) each
Contract for the acquisition of any Person or any business unit thereof or the disposition of any material assets of the Company;
and

 

(k) each
Contract that is otherwise material to the Transferred Business.

 

“Merger
Consideration” means (i) the Buyer Shares and (ii) one contractual contingent value right per Buyer Share (each,
a “CVR”), which shall represent the right to receive contingent distributions upon the achievement of
certain milestones, and as variable distributions based upon Net Sales (as defined in the CVR Agreement), subject to and in accordance
with the terms and conditions of the CVR Agreement.

 

    8

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
 BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE
 THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

    

 

“Merger
One Certificate of Merger” means the certificate of merger, in the form prescribed by the NJBCA, setting forth Merger
One.

 

“Merger
One Effective Time” means the time at which the Merger One Certificate of Merger has been duly filed with the New
Jersey State Treasurer, and has become effective in accordance with the NJBCA or at such later time as may be agreed by the Parties
in writing and specified in the Merger One Certificate of Merger.

 

“Merger
Two Certificate of Merger” means the certificate of merger, in the form prescribed by the NJBCA, setting forth Merger
Two.

 

“Merger
Two Effective Time” means the time at which the Merger Two Certificate of Merger has been duly filed with the New
Jersey State Treasurer in accordance with the NJBCA, or at such later time as may be agreed by the Parties in writing and specified
in the Merger Two Certificate of Merger, which, in either case, shall be as promptly as practicable after the Merger One Effective
Time (and in no event prior to the Merger One Effective Time).

 

“Non-Customized
Licensed Software” means all non-customized software that is (a) solely in executable or object code form pursuant
to a non-exclusive, internal use software license; (b) is not incorporated into, or used directly in connection with the Company
Program Products; and (c) is generally available on standard terms for less than $10,000.

 

“Party”
means each of Buyer, Merger Sub 1, Merger Sub 2, the Company and Seller.

 

“Patents”
means (a) patents and patent applications (provisional and non-provisional) anywhere in the world, (b) all divisionals, continuations,
continuations-in-part thereof, or any other patent application claiming priority, or entitled to claim priority, directly or indirectly
to (i) any such patents or patent applications or (ii) any patent or patent application from which such patents or patent applications
claim, or is entitled to claim, direct or indirect priority, and (c) all patents issuing from any of the foregoing anywhere in
the world, together with all registrations, reissues, re-examinations, patents of addition, renewals, supplemental protection
certificates, or extensions of any of the foregoing anywhere in the world.

 

“PDA-001”
means CD10+, CD34–, CD105+, CD200+ placenta-derived adherent cells, proprietary to the Company, that are formulated for
intravenous delivery.

 

“PDA-002”
means CD10+, CD34–, CD105+, CD200+ placenta-derived adherent cells, proprietary to the Company that are formulated for subcutaneous
or intramuscular delivery.

 

“Permitted
Liens” means (i) Liens for Taxes or similar governmental assessments and charges, which are either not delinquent
or being contested in good faith and by appropriate proceedings or (ii) mechanics’, materialmen’s or contractors’
Liens or any similar statutory Lien or restriction for amounts not yet due or payable.

 

    9

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
 BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE
 THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

    

 

“Person”
means any individual, person, entity, general partnership, limited partnership, limited liability partnership, limited liability
company, corporation, joint venture, trust, business trust, cooperative, association, foreign trust, foreign business organization
or a Governmental Entity.

 

“PNK-007”
means natural killer cells proprietary to the Company, produced by a process proprietary to the Company as of the Closing Date.

 

“PNK-007
Program” means the Company’s PNK-007 program, which for the avoidance of doubt does not include the CAR-NK
Program or the Genetically Modified NK Cell Program.

 

“Post-Closing
Tax Periods” means taxable periods ending after the Closing Date and, with respect to any Straddle Period, the portion
of such Straddle Period beginning immediately after the Closing Date.

 

“Pre-Closing
Tax Periods” means taxable periods ending on or before the Closing Date and, with respect to any Straddle Period,
the portion of such Straddle Period ending on the Closing Date.

 

“Prohibited
Person” means (i) a Person who is a “designated national,” “specially designated national,”
“specially designated terrorist,” “specially designated global terrorist,” “foreign terrorist organization,”
“specially designated narcotics trafficker,” or “blocked person,” within the definitions set forth in
the Foreign Assets Control Regulations contained in 31 C.F.R., Subtitle B, Chapter V, or who otherwise appears on the list of
Specially Designated Nationals and Blocked Persons in Appendix A thereto, or (ii) the government, including any political subdivision,
agency, instrumentality, or national thereof, of any country against which the United States maintains economic sanctions or embargos.

 

“Regulatory
Approval” means any approvals, clearances, authorizations, registrations, certifications, licenses and permits granted
by a Regulatory Authority in a country or region and necessary to commercially manufacture, market and sell a product in such
country or region in accordance with applicable Laws, including EMA Regulatory Approval and US Regulatory Approval.

 

“Regulatory
Authority” means, with respect to a country or region, any national (e.g., the FDA for the United States), supra-national,
regional, state or local regulatory agency, department, bureau, commission, council or other Governmental Entity involved in the
granting of any approval required by applicable Law to promote, market and sell pharmaceutical products in such country or region
or, to the extent required in such country or region, price approval, for pharmaceutical products in such country or region.

 

“Representative”
means, with respect to a particular Person, any director, officer, employee, member, manager, agent, consultant, advisor or other
representative of such Person, including legal counsel, accountants and financial advisors.

 

    10

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
 BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE
 THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

    

 

“Seller
Fundamental Representations” means the representations and warranties of Seller and the Company, as applicable,
in Section 3.1 (Organization, Qualification and Power), Section 3.2 (Authorization; Binding Effect),
Section 3.4 (Brokerage), Section 3.5 (Capitalization), Section 4.1 (Organization, Qualification
and Power), Section 4.2 (Authorization; Binding Effect), Section 4.4 (Brokerage) and Section
4.5 (Investment Related Representations and Warranties).

 

“Seller
Transaction Expenses” means, without duplication, (a) the aggregate third party legal, accounting, consulting, investment
banking, financial advisory, brokerage and other third party fees and expenses incurred by or on behalf of the Company in connection
with this Agreement, the Transaction Documents and the Contemplated Transactions; and (b) any such fees and expenses incurred
by Seller or its Affiliates to be paid for by the Company.

 

“Shareholders’
Agreements” means (i) the Investors’ Rights Agreement by and among Buyer and the shareholders thereof (including
Seller) in the form attached hereto as Exhibit C, (ii) the Voting Agreement by and among Buyer and the shareholders
thereof (including Seller) in the form attached hereto as Exhibit D, and (iii) an Investment Rights Agreement between
Buyer and Seller in the form attached hereto as Exhibit E, in each case, to be entered into as of the Closing Date.

 

“Stock
Purchase Agreement” means the Series A Preferred Stock Purchase Agreement between Buyer and the Investors attached
hereto as Exhibit F.

 

“Straddle
Period” means any taxable period beginning before and ending after the Closing Date.

 

“Subsidiary”
means, with respect to any Person, any corporation, limited liability company, partnership, association or other business entity
of which (a) if a corporation or a limited liability company (with voting securities) a majority of the total voting power of
shares of stock or other securities entitled (without regard to the occurrence of any contingency) to vote in the election of
directors, managers or trustees thereof is at the time owned or controlled (or would be owned or controlled upon exercise of all
options and warrants to purchase such voting securities), directly or indirectly, by that Person or one or more of the other Subsidiaries
of that Person or a combination thereof, or (b) if a limited liability company (without voting securities), partnership, association
or other business entity, a majority of the partnership or other similar ownership interest thereof is at the time owned or controlled
(or would be owned or controlled upon exercise of all options and warrants to purchase such partnership or other similar ownership
interest), directly or indirectly, by any Person or one or more Subsidiaries of that Person or a combination thereof. For purposes
hereof, a Person or Persons shall be deemed to have a majority ownership interest in a limited liability company, partnership,
association or other business entity if such Person or Persons shall be allocated a majority of limited liability company, partnership,
association or other business entity gains or losses or shall be or control any managing director or general partner of such limited
liability company, partnership, association or other business entity.

 

“Tax”
or “Taxes” means (a) any and all U.S. federal, state, local or non-U.S. taxes, charges, fees, imposts,
levies or other assessments, including all net income, gross receipts, service, capital, sales, use, ad valorem, value added,
transfer, franchise, profits, inventory, capital stock, license, net worth, withholding, payroll, employment, social security,
unemployment, excise, severance, stamp, transfer and recording taxes, escheat, unclaimed property obligations, occupation, real
or personal property and estimated taxes, customs duties, fees, assessments and charges of any kind whatsoever; and (b) all interest,
penalties, fines, additions to tax or additional amounts imposed by the IRS or any other taxing authority in connection with any
item described in clause (a).

 

    11

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
 BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE
 THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

    

 

“Tax
Proceeding” means any Action involving Taxes. For the avoidance of doubt, the term “Tax Proceeding”
shall not include any Tax Proceeding with respect to any combined, consolidated, or unitary group for which Seller is a member.

 

“Tax
Return” means any return, declaration, report, claim for refund, or information return or statement relating to
Taxes, including any schedule or attachment thereto, and including any amendment thereof, in each case, filed with a Governmental
Entity. For the avoidance of doubt, the term “Tax Return” shall not include any Tax Return filed with respect to any
combined, consolidated, or unitary group other than a group whose sole members are the Company and any Subsidiaries thereof.

 

“Transaction
Documents” means the Transition Services Agreement, the License Agreement, the Shareholders Agreements, the CVR
Agreement, the Merger One Certificate of Merger, the Merger Two Certificate of Merger, and any other agreement, certificate, instrument
or other document to be executed and delivered pursuant hereto, as contemplated hereby or in connection with the consummation
of the transactions contemplated by this Agreement.

 

“Transfer
Taxes” means all sales, use, value added, gross receipts, excise, transfer, intangible, recordation, documentary
stamp, duty or similar Taxes or charges, of any nature whatsoever (including any penalties and interest).

 

“Transferred
Business” means the business and operations of the Company as conducted by the Company immediately prior to the
Agreement Date; provided, however, that the term “Transferred Business” shall not include the BCMA CAR-T Program,
the CAR-NK Program or the CTL Program.

 

“Transition
Services Agreement” means that certain Transition Services Agreement to be entered by and between Buyer, the Company
and Seller at Closing in the form to be mutually agreed by the parties.

 

“TST-001”
means a culture-expanded, antigen-specific, T-cell population derived from autologous peripheral blood mononuclear cells in dosage
form for intravenous administration.

 

“US
Regulatory Approval” means approval granted by the FDA as evidenced by publication of approval by the FDA of an
MAA to market and sell a Company Program Product in the United States for a particular indication. For the avoidance of doubt,
an “approval letter” or similar communication published by the FDA shall not constitute approval for the purposes
of the foregoing.

 

    12

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
 BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE
 THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

    

 

“Valid
Claim” means a claim of (a) an issued patent in the U.S. or in a jurisdiction outside the U.S., as applicable, that
has not expired, lapsed, been cancelled or abandoned, or been dedicated to the public, disclaimed, or held unenforceable, invalid,
revoked or cancelled by a court or administrative agency of competent jurisdiction in an order or decision from which no appeal
has been or can be taken, including through opposition, reexamination, reissue, disclaimer, inter partes review, post grant review,
other post grant procedures or similar proceedings; or (b) a pending patent application that has not been finally abandoned or
finally rejected or expired and which has been pending for no more than seven (7) years (or, in the case of any such pending patent
application in Canada or Japan, eight (8) years) from the date of that the prosecuting Party first receives a substantive office
action for such application for a Patent (excluding restriction requirements, notices to file missing parts, and the like). For
clarity, a claim which issues after being pending for more than seven (7) years (or, in the case of any such pending patent application
in Canada or Japan, eight (8) years) from the date of the first substantive office action as described in (b) above shall be considered
a Valid Claim as of the date of issuance.

 

Additional
Defined Terms. Each of the following terms is defined in the Section set forth opposite such term:

 

	TERM	 	SECTION
	Agreement 	 	Preamble
	Bankruptcy
    and Equity Exception 	 	3.2
	Buyer 	 	Preamble
	Buyer
    DC Plan 	 	6.6(e)
	Buyer
    Indemnification Claim 	 	9.1(a)
	Buyer
    Indemnified Persons 	 	9.1(a)
	Closing
     	 	2.3
	Closing
    Date 	 	2.3
	Company 	 	Preamble
	Company
    Employees 	 	6.6(a)
	Company
    Information 	 	6.12(c)
	Defaulting
    Party  	 	8.2
	Disclosure
    Schedules  	 	Article
    III
	Finally
    Determined 	 	9.3(f)
	Financing
     	 	5.6
	Financing
    Document 	 	6.12(a)
	Governmental
    Permits 	 	3.7
	Indemnified
    Person 	 	9.2(a)
	Indemnifying
    Person 	 	9.2(a)
	Investor
     	 	5.6
	Merger
    One Surviving Entity 	 	2.1(a)
	Notice
    of Claim 	 	9.2(a)
	Objection
    Notice  	 	9.2(a)
	Outside
    Date  	 	8.1(b)
	Response
    Period 	 	9.2(a)
	Securities
    Act  	 	4.5(b)
	Seller 	 	Preamble
	Seller
    Indemnified Persons  	 	9.1(b)
	Seller’s
    Marks  	 	6.5
	Shares
     	 	Recitals
	Surviving
    Entity  	 	2.2(a)
	Third
    Party Claim 	 	9.2(b)
	Third
    Party Notice 	 	9.2(b)
	Value
     	 	9.3(f)

 

    13

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
 BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE
 THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

    

 

Section
1.2 Interpretation and Rules of Construction. Unless otherwise
indicated to the contrary herein by the context or use thereof:

 

(a)
a capitalized term has the meaning assigned to it;

 

(b)
when a reference is made in this Agreement to an Article, Section, Exhibit or Schedule, such reference is to an Article or Section
of, or an Exhibit or Schedule to, this Agreement;

 

(c)
the table of contents and headings for this Agreement are for reference purposes only and do not affect in any way the meaning
or interpretation of this Agreement;

 

(d)
the words, “herein,” “hereto,” “hereof” and words of similar import refer to this Agreement
as a whole and not to any particular Section or paragraph hereof;

 

(e)
references to “including” in this Agreement shall mean “including, without limitation,” whether or not
so specified;

 

(f)  references in the singular or to “him,” “her,” “it,” “itself,” or other like references,
and references in the plural or the feminine or masculine reference, as the case may be, shall also, when the context so requires,
be deemed to include the plural or singular, or the masculine or feminine reference, as the case may be;

 

(g)
references to any statute shall be deemed to refer to such statute as amended from time to time and to any rules or regulations
promulgated thereunder;

 

(h)
all accounting terms used herein and not expressly defined herein shall have the meanings assigned to such terms in accordance
with GAAP;

 

(i)
all terms defined in this Agreement have the defined meanings when used in any certificate or other document made or
delivered pursuant hereto, unless otherwise defined therein; and

 

(j)
all references to “$” will be references to United States Dollars, and with respect to any Contract, obligation,
liability, claim or document that is contemplated by this Agreement, but denominated in currency other than United States
Dollars, the amounts described in such Contract, obligation, liability, claim or document will be deemed to be converted into
United States Dollars for purposes of this Agreement based on the noon buying rate in New York, as certified weekly by the
Federal Reserve Bank of New York, in effect as of the applicable date of determination.

 

    14

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
 BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE
 THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

    

 

Article
II

THE MERGERS; CLOSING

 

Section
2.1 Merger One.

 

(a)
Upon the terms and subject to the conditions set forth in this Agreement, and in accordance with the NJBCA, at the Merger One
Effective Time, Merger One shall be consummated with Merger Sub 1 being merged with and into the Company. As a result of Merger
One, the separate corporate existence of Merger Sub 1 shall cease, and the Company shall continue as the surviving corporation
under the Laws of the State of New Jersey (“Merger One Surviving Entity”), with such effects as set
forth in the NJBCA.

 

(b)
At the Merger One Effective Time, as a result of Merger One and without any action on the part of Buyer, Merger Sub 1, the Company
or Seller (i) any shares of common stock of the Company that are owned by the Company (as treasury stock or otherwise) shall be
automatically canceled and retired and shall cease to exist, (ii) the Shares shall be converted into the right to receive the
Merger Consideration, which Buyer shall deliver to Seller in accordance with Section 2.4(a) and the CVR Agreement,
and (iii) each share of common stock of Merger Sub 1 issued and outstanding immediately prior to the Merger One Effective
Time shall be converted into and become one newly issued, fully paid and non-assessable share of common stock of Merger One Surviving
Entity.

 

(c)
At the Merger One Effective Time, (i) the certificate of incorporation of the Company as in effect immediately prior to the Merger
One Effective Time shall be the certificate of incorporation of the Merger One Surviving Entity, until thereafter amended in accordance
with the terms thereof or as provided by applicable Law, and (ii) the by-laws of the Company as in effect immediately prior to
the Merger One Effective Time shall be the by-laws of Merger One Surviving Entity, until thereafter amended in accordance with
the terms thereof, the certificate of incorporation of Merger One Surviving Entity or as provided by applicable Law.

 

Section
2.2 Merger Two.

 

(a)
Upon the terms and subject to the conditions set forth in this Agreement, and in accordance with the NJBCA, at the Merger Two
Effective Time, Merger Two shall be consummated with Merger One Surviving Entity being merged with and into Merger Sub 2 (which
is an entity treated for U.S. federal income tax purposes as an entity that is disregarded as an entity separate from its owner,
within the meaning of Section 301.7701-3(b) of the U.S. Treasury Regulations promulgated pursuant to the Code). As a result of
Merger Two, the separate corporate existence of Merger One Surviving Entity shall cease, and Merger Sub 2 shall continue as a
surviving limited liability company under the Laws of the State of New Jersey (the “Surviving Entity”),
with such effects as set forth in the NJBCA.

 

(b)
At the Merger Two Effective Time, as a result of Merger Two and without any action on the part of Buyer, Merger Sub 2 or Merger
One Surviving Entity, all shares of capital stock of Merger One Surviving Entity, whether issued and outstanding or owned by the
Merger One Surviving Entity as treasury shares, shall cease to exist and no consideration shall be delivered in exchange therefor.

 

    15

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
 BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE
 THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

    

 

(c)
At the Merger Two Effective Time, (i) the certificate of formation of Merger Sub 2 as in effect immediately prior to the Merger
Two Effective Time shall be the certificate of formation of the Surviving Entity until thereafter amended in accordance with the
terms thereof or as provided by applicable Law, and (ii) the limited liability company agreement of Merger Sub 2 as in effect
immediately prior to the Merger Two Effective Time shall be the limited liability company agreement of the Surviving Entity until
thereafter amended in accordance with the terms thereof, the certificate of formation of the Surviving Entity or as provided by
applicable Law.

 

Section
2.3 The Closing. Subject to Section 8.1, the
closing of the Mergers (the “Closing”) shall take place at the offices of Proskauer Rose LLP, Eleven
Times Square, New York, New York 10036 (or at such other location as the Parties may agree), commencing at 10:00 a.m. local time
on the third Business Day immediately following the day on which the last of the conditions specified in Sections 7.1,
7.2 and 7.3 (other than those conditions that by their nature are to be satisfied at the Closing or
on the Closing Date, but subject to the satisfaction or waiver of those conditions) are satisfied or waived in accordance with
this Agreement, or on such other date as Parties may otherwise agree. The day on which the Closing actually occurs is referred
to herein as the “Closing Date.”

 

Section
2.4 Issuance of the Buyer Shares; Closing Deliverables.
Subject to the satisfaction or waiver of each of the conditions specified in Sections 7.1, 7.2 and
7.3, as applicable:

 

(a)
At the Closing, upon the terms and subject to the conditions set forth in this Agreement, Buyer shall issue to Seller the Buyer
Shares and, in connection therewith, shall deliver (electronically) to Seller a copy of the certificate(s) issued in the name
of Seller and representing the Buyer Shares.

 

(b)
At the Closing, Buyer shall deliver or cause to be delivered to Seller:

 

(i)
duly executed counterparts of each of the Transaction Documents (other than this Agreement) to which Buyer is a party;

 

(ii)
a certificate of a senior executive officer (or such other authorized Person, as applicable) of Buyer certifying as of the Closing
as to the fulfillment of the conditions set forth in Sections 7.3(a) and (b) hereof; and

 

(iii)
a certificate, dated within five (5) days prior to the Closing, of the Secretary of State of Delaware establishing that Buyer
is in existence and good standing under the Laws of the State of Delaware.

 

(c)
At the Closing, Seller shall deliver or cause to be delivered to Buyer:

 

(i)
duly executed counterparts of each of the Transaction Documents (other than this Agreement) to which Seller or the Company is
a party;

 

    16

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
 BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE
 THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

    

 

(ii)
duly executed copies of the third party consents, waivers and approvals listed on Schedule 2.4(c)(ii);

 

(iii)
a certificate of a senior executive officer (or such other authorized Person, as applicable) of Seller certifying as of the Closing
as to the fulfillment of the conditions set forth in Sections 7.2(a) and (b) hereof;

 

(iv)
written resignations, effective as of the Closing, of the officers and directors of the Company;

 

(v)
an IRS Form W-9 duly executed by Seller; and

 

(vi)
an executed certificate pursuant to Treasury Regulations section 1.1445-2(b) that Seller is not a foreign person within the meaning
of Section 1445(b)(2) of the Code.

 

Section
2.5 Withholding. Buyer shall be entitled to withhold and
deduct from any consideration payable or otherwise deliverable pursuant to this Agreement such amounts as Buyer is required to
deduct and withhold therefrom under the Code or any provision of state, local, or non-U.S. Tax Law. Buyer shall timely deduct,
withhold, and pay over any deducted or withheld amounts to the appropriate Governmental Entity and any such amounts that are so
deducted or withheld and paid over to the appropriate Governmental Entity shall be treated for all purposes of this Agreement
as having been paid to the Person to whom such amounts would otherwise have been paid.

 

Section
2.6 Tax Treatment. Each Party agrees, for U.S. federal income
tax purposes and as of the Agreement Date, except as may otherwise be required by applicable Law, that the Mergers are intended
to be treated as an integrated transaction and shall qualify as a “reorganization” under Section 368(a) of the Code,
(iii) that the Agreement has been adopted as a plan of reorganization within the meaning of Treasury Regulation Section 1.368-2(g)
and 1.368-3(a), and (iv) except as otherwise required by applicable Law, to take no action inconsistent with such treatment (including
in any applicable Tax Returns).

 

Article
III

REPRESENTATIONS AND WARRANTIES OF THE COMPANY

 

As
a material inducement to Buyer to enter into this Agreement and to consummate the Contemplated Transactions, except as set forth
in the disclosure schedules delivered by Seller to Buyer on the Agreement Date prior to execution of this Agreement (the “Disclosure
Schedules”), the Company hereby represents and warrants to Buyer, as of the Agreement Date and the Closing Date,
as follows:

 

    17

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
 BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE
 THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

    

 

Section
3.1 Organization, Qualification and Organizational Power.
The Company is a corporation duly incorporated, validly existing and in good standing under the Laws of the State of New Jersey
and has all necessary power and authority to enter into this Agreement and the Transaction Documents to which it is a party, to
carry out its obligations hereunder and thereunder and to consummate the Contemplated Transactions. The Company is duly licensed
or qualified to do business and is in good standing in each jurisdiction in which the properties owned or leased by it and the
operation of the Transferred Business as currently conducted by it makes such licensing or qualification necessary, except to
the extent that the failure to be so licensed, qualified or in good standing would not have a Material Adverse Effect. The Company
has full corporate power and authority to carry on the Transferred Business as currently conducted, and to own, lease or operate,
as applicable, its assets and properties and to perform its obligations under its Contracts.

 

Section
3.2 Authorization; Binding Effect. The execution and delivery
by the Company of this Agreement and the Transaction Documents to which it is a party, the performance by it of its obligations
hereunder and thereunder and the consummation by it of the Contemplated Transactions have been duly authorized by all requisite
action on the part of the Company. This Agreement has been, and upon their execution the Transaction Documents shall have been,
duly executed and delivered by the Company, and (assuming due authorization, execution and delivery by the other parties) this
Agreement constitutes, and upon their execution the Transaction Documents shall constitute, legal, valid and binding obligations
of the Company which are enforceable against the Company in accordance with their respective terms, except as such enforceability
may be limited by (i) applicable insolvency, bankruptcy, reorganization, moratorium or other similar Laws affecting creditors’
rights generally, and (ii) applicable equitable principles (whether considered in a proceeding at Law or in equity) (the “Bankruptcy
and Equity Exception”).

 

Section
3.3 Approvals and Consents.

 

(a)
Except as set forth on Section 3.3(a) of the Disclosure Schedules and except as may be required by the HSR Act and
any other applicable Antitrust Laws, to the Knowledge of the Company, the execution, delivery and performance of this Agreement
and each Transaction Document by the Company does not and will not require any material consent, approval, authorization or other
order or declaration of, action by, filing with, notification to or permit from, any Governmental Entity, except as may be necessary
as a result of any facts or circumstances relating solely to Buyer or any of its Affiliates.

 

(b)
Assuming the making and obtaining of all filings, notifications, consents, approvals, authorizations and other actions referred
to in Section 3.3(a) and Sections 3.3(a) of the Disclosure Schedules, and except as set forth on Section
3.3(b) of the Disclosure Schedules or as may result from any facts or circumstances relating solely to Buyer, the execution,
delivery and performance of this Agreement and the Transaction Documents by the Company does not and will not (i) violate, conflict
with or result in the breach of the organizational documents of the Company, (ii) conflict with or violate any Law or Governmental
Order applicable to the Company or any Governmental Permit, or (iii) conflict with, result in any breach of, constitute a default
(or event which with the giving of notice or lapse of time, or both, would become a default) under, require any consent under,
or give to others any rights of termination, acceleration or cancellation of, any Contract of the Company, except, in the case
of clauses (ii) or (iii), as would not have a Material Adverse Effect.

 

    18

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
 BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE
 THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

    

 

Section
3.4 Brokerage. The Company does not have any liability or
obligation to pay any fees or commissions to any broker, finder, or agent with respect to the Contemplated Transactions for which
Buyer or any of its Affiliates could become liable or obligated.

 

Section
3.5 Capitalization.

 

(a)
The authorized capital stock of the Company consists of 10,000 shares, of which 1,000 shares are issued and outstanding and constitute
the Shares. All of the Shares have been duly authorized and are validly issued, fully paid and non-assessable and have not been
issued in violation of any Laws. None of the Shares were issued or transferred in violation of any agreement, arrangement or commitment
to which Seller or the Company is a party or is subject or in violation of any preemptive or similar rights of any Person.

 

(b)
Except as set forth on Section 3.5(b) of the Disclosure Schedules, there are no outstanding subscriptions, options,
rights, warrants, rights of first refusal or offer, preemptive rights or other commitments of any character entitling any Person
to purchase or otherwise subscribe for or acquire any capital stock of the Company or any security convertible into or exchangeable
for capital stock of the Company, nor is there presently outstanding any security convertible into or exchangeable for capital
stock or equity interests of the Company, nor has the Company entered into any agreement with respect to any of the foregoing.
Except as set forth on Section 3.5(b) of the Disclosure Schedules, the Company has no obligation to repurchase,
redeem or otherwise acquire any capital stock, equity interests or voting interests in the Company. There are no irrevocable proxies
and no voting agreements to which the Company is a party with respect to any capital stock or other voting securities of the Company,
and except as set forth on Section 3.5(b) of the Disclosure Schedules, there are no voting trusts, stockholder agreements,
proxies or other agreements or understandings in effect with respect to the voting or transfer of any of the capital stock of
the Company.

 

(c)
No distributions or dividends have been declared with respect to any capital stock of the Company the record or payment date for
which is on or after the Agreement Date or which are currently unpaid.

 

(d)
The Company does not own, or have any interest in the capital stock of, or any other ownership interest in, any Person.

 

Section
3.6 Assets. Except as set forth on Section 3.6
of the Disclosure Schedules, the assets and properties owned, leased or licensed by the Company together with the services to
be provided, and rights to be licensed, to the Company pursuant to the Transition Services Agreement and the License Agreement
constitute all of the material assets and properties used in the operation of the Transferred Business.

 

Section
3.7 Governmental Permits. The Company holds or possesses
the licenses, franchises, permits, approvals and other authorizations from Governmental Entities listed in Section 3.7
of the Disclosure Schedules (collectively, the “Governmental Permits”). The Company is in compliance
in all material respects with all such Governmental Permits. Except as set forth on Section 3.7 of the Disclosure
Schedules, the Governmental Permits are in full force and effect. As of the Agreement Date, no proceeding is pending or, to the
Knowledge of the Company, threatened to revoke any Governmental Permit.

 

    19

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
 BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE
 THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

    

 

Section
3.8 Employees and Employment Matters.

 

(a)
Neither the Company nor any of its ERISA Affiliates has incurred any liability, contingent or otherwise, under or arising out
of Title IV of ERISA that has not been satisfied in full (other than any liability for standard premiums payable to the Pension
Benefit Guaranty Corporation arising in the ordinary course), and no fact or event exists that has or could be expected to result
in such a liability.

 

(b)
Section 3.8(b) of the Disclosure Schedules sets forth for each Company Employee: (i) the employee’s name,
(ii) position or title and supervisor, (iii) state(s) in which the employee performs services, (iv) base salary, (v) bonus target,
(vi) whether or not such employee has an employment agreement or offer letter providing severance or change of control-related
benefits (and if applicable, the details of those benefits), (vii) status as an exempt or non-exempt employee, and (viii) whether
any Company Employee is part-time, or is currently on leave of absence or otherwise unable to render services in a full-time capacity.

 

(c)
The Company is not party to any collective bargaining agreement and is not, and has not previously been, the subject of any collective
bargaining or union organizing activity.

 

(d)
With respect to employees of the Transferred Business, except as would not individually or in the aggregate reasonably be likely
to have a Material Adverse Effect, to the Company’s Knowledge the Company is in compliance with all applicable Laws relating
to the employment of employees of the Transferred Business (including employment or labor standards, labor relations, occupational
health and safety, workers’ compensation, severance payment, employment equity and pay equity) and has paid in full all
wages, salaries, commissions, other compensation and benefits and all levies, assessments, contributions and payments to third
parties (including social security or social insurance, housing fund, employment insurance, income tax, employer health tax, workers
compensation, or payments of its contributions with respect to social security agencies, family benefits agencies and any retirement
and unemployment related agencies or other payments of Tax and social security payments to Governmental Entities) due to or on
behalf of such employees. No material claim with respect to payment of wages, salary or overtime pay has been asserted, or is
now pending or, to the Company’s Knowledge, threatened before any Governmental Entity, with respect to current or former
employees of the Transferred Business, and there is no material charge or proceeding with respect to a violation of any occupational
safety or health standards that has been asserted or is now pending or, to the Company’s Knowledge, threatened with respect
to the Transferred Business. No material charge of discrimination in employment or employment practices for any reason, including
age, gender, race, religion or other legally protected category, has been asserted or is now pending or, to the Company’s
Knowledge, threatened before the United States Equal Employment Opportunity Commission or other Governmental Entity by current
or former employees of the Transferred Business. Except as would not individually or in the aggregate reasonably be likely to
have a Material Adverse Effect, the Company is not subject to any pending investigation from any labor inspection or similar Governmental
Entity with respect to the Transferred Business which could reasonably be expected to result in any liability. There is currently
no Action that has been brought or, to the Company’s Knowledge, threatened with respect to current or former employees of
the Transferred Business. Except as would not individually or in the aggregate reasonably be likely to have a Material Adverse
Effect, there are no outstanding, unsatisfied obligations to comply with any recommendation or declaration of any Governmental
Entity in respect of any of the current or former employees of the Transferred Business. The Company has not taken any action
that could constitute a “mass layoff”, “mass termination” or “plant closing” within the meaning
of The Worker Adjustment and Retraining Notification Act (WARN) or otherwise trigger notice requirements or liability under any
federal, local, provincial, state or foreign plant closing notice, redundancy or collective dismissal law.

 

    20

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
 BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE
 THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

    

 

Section
3.9 Real and Personal Property.

 

(a)
The Company does not now own, nor since 2003 has it owned, any real property, nor does it hold an option to acquire any real property.
Section 3.9(a) of the Disclosure Schedules sets forth a list of each lease or similar agreement under which the
Company is lessee of, or holds or operates, any real property owned by any third Person.

 

(b)
Section 3.9(b) of the Disclosure Schedules contains a list of all machinery and equipment used by the Company in
the production of the Company Program Products, having an original cost of $100,000 or more.

 

Section
3.10  No Violation, Litigation or Regulatory Action.

 

(a)
Except as set forth in Section 3.10 of the Disclosure Schedules:

 

(i)
The Company is not, and during the last three years has not been, subject to or bound by any Governmental Order;

 

(ii)
The Company is, and during the last three years has been, in compliance in all material respects with applicable Laws;

 

(iii)
There are not now, nor in the last three years has there been, any Actions pending or, to the Knowledge of the Company, threatened
in writing against or involving the Company;

 

(iv)
There are no Actions pending in which the Company is the plaintiff or claimant;

 

(v)
There is not now, nor in the last three years has there been, any Action against or involving the Company by, nor has the Company
received any written notice, charge or assertion from, any Governmental Entity alleging any material violation of applicable Law,
and to the Knowledge of the Company, no such notice, charge, assertion or Action is threatened.

 

    21

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
 BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE
 THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

    

 

(vi)
Since January 1, 2014, neither the Company nor, to the Knowledge of the Company, any director, officer or employee of the Company
in their capacity as such has (i) conducted business with a Prohibited Person, (ii) used any funds for unlawful expenses related
to political activity or (iii) made any unlawful payment or unlawfully offered anything of value to foreign or domestic government
officials or employees or to foreign or domestic political parties or campaigns.

 

Section
3.11  Intellectual Property.

 

(a)
Section 3.11(a) of the Disclosure Schedules sets forth a true, complete and accurate list of all Company Registered
Intellectual Property (showing in each case the registered or other owners, filing date, date of issuance, and registration or
application number, if any).

 

(b)
The Company owns and, immediately following the Closing the Surviving Entity will own, exclusive right, title and interest in
and to all Owned Intellectual Property, free and clear of any Liens, other than (x) Liens arising from actions taken by Buyer
or its Affiliates, and (y) Permitted Liens. All Licensed Intellectual Property, other than Non-Customized Licensed Software, is
licensed to Company pursuant to a Contract identified on Section 3.11(b) of the Disclosure Schedules and is identified
on Section 3.11(b) of the Disclosure Schedules. The Company Intellectual Property, other than the Licensed Intellectual
Property, is referred to in this Agreement as the “Owned Intellectual Property.” “Owned
Intellectual Property” consists of Company Intellectual Property licensed to Human Longevity, Inc. (the “HLI-Licensed
Intellectual Property”) and Company Intellectual Property not licensed to HLI (the “Retained Intellectual
Property”). Section 3.11(a) of the Disclosure Schedules sets out HLI Licensed Intellectual Property
and Retained Intellectual Property separately.

 

(c)
The Company is not bound by, and no Owned Intellectual Property is subject to, any Governmental Order that in any way limits or
restricts the ability of Company to use, exploit, assert, or enforce the Owned Intellectual Property, or that affects the validity,
enforceability, or Company’s (or the Surviving Entity’s) ownership of any Owned Intellectual Property. Other than
the HLI-Licensed Intellectual Property, the Company has not agreed to assign or otherwise transfer ownership of, or license exclusive
rights to, any Company Intellectual Property to any Person.

 

(d)
The Company has the sole and exclusive right to bring Actions for infringement, misappropriation, dilution, violation or unauthorized
use of the Retained Intellectual Property. No interferences, re-examinations, oppositions, cancellation proceedings, post-grant
reviews, pre-issue submission, derivation proceedings or other Actions pertaining to the Company Registered Intellectual Property
within the Retained Intellectual Property are pending or, to the actual knowledge of the Company (without any duty of inquiry),
threatened. To the actual knowledge of the Company (without any duty of inquiry), the Company is not in material breach of or
default under any Contract affecting the Company Intellectual Property.

 

    22

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
 BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE
 THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

    

 

(e)
The Company has not received any written notice regarding the enforceability or validity of any of the Patents included in the
Company Registered Intellectual Property. All necessary registration, maintenance and renewal fees currently due as of the Effective
Date in connection with Company Registered Intellectual Property within the Retained Intellectual Property have been made and,
to the actual knowledge of the Company (without any duty of inquiry), all necessary documents, recordations and certifications
currently required in connection with such Company Registered Intellectual Property within the Retained Intellectual Property
have been filed with the relevant Government Authority for the purpose of maintaining and recording such Company Registered Intellectual
Property in the name of the Company. No action (other than actions in the ordinary course of business) must be taken by the Company
(or the Surviving Entity) within 120 days after the Closing Date to obtain, maintain, perfect or renew any Company Registered
Intellectual Property within the Retained Intellectual Property, except as set forth on Section 3.11(e) of the Disclosure
Schedules.

 

(f)
To the actual knowledge of the Company (without any duty of inquiry), no Person is engaging in any activity that infringes upon,
misappropriates or otherwise violates any material Retained Intellectual Property or Licensed Intellectual Property. The consummation
of the Contemplated Transactions will not reasonably be expected to give rise to, result in or serve as a basis for the termination
or impairment of any material Company Intellectual Property, give rise to, result in or serve as a basis for any material breach
or default under any material Contract or license relating to any Company Intellectual Property, or give any Person (other than
Buyer) any right to terminate or alter any Company Intellectual Property or any Contract or license related thereto.

 

(g)
The Company has taken commercially reasonable steps to maintain the confidentiality of the Know-How of the Company and other confidential
Company Intellectual Property. The actual knowledge of the Company (without any duty of inquiry), no material misappropriation,
unauthorized disclosure or use of Know-How of the Company or other Company Intellectual Property has occurred.

 

Section
3.12  Material Contracts.

 

(a)
Section 3.12(a) of the Disclosure Schedules sets forth a list of the Material Contracts in effect as of the Agreement
Date and, to the extent any such Material Contracts are oral, a description of the material terms thereof.

 

(b)
Each Material Contract is valid, binding, in full force and effect and enforceable in accordance with its terms, subject to the
Bankruptcy and Equity Exception. Except as set forth on Section 3.12(b) of the Disclosure Schedules, the consummation
of the transactions contemplated by this Agreement will not result in a material breach of a Material Contract or the forfeiture
or impairment of a material right under a Material Contract.

 

(c)
Neither the Company, Seller, nor, to the Knowledge of Company, any other party to any Material Contract is in material breach
of or default under any Material Contract nor has the Company or Seller received any written notice since January 1, 2016 regarding
(i) any actual or alleged material breach of or default under any Material Contract or (ii) any intention of any party to any
Material Contract to cancel or terminate such Material Contract. Except in the ordinary course of business consistent with past
practice, no Material Contract is currently being renegotiated by the Company, and the Company has not received any written notice
of any demand for such renegotiation since January 1, 2016.

 

    23

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
 BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE
 THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

    

 

Section
3.13  Taxes. Except as set forth in Section 3.13 of the Disclosure
Schedules, and only to the extent that, individually or in the aggregate, a failure of any of the following to be true would result
in a Material Adverse Effect:

 

(a)
The Company has timely filed all Tax Returns that it was required to have filed, and all such Tax Returns are correct and complete
in all respects, and were prepared in compliance with all applicable laws.

 

(b)
All Taxes due and owing by the Company (whether or not shown on any Tax Returns) have been paid in full, except for any such Taxes
that are being contested in good faith by appropriate proceedings and for which adequate reserves are being maintained in accordance
with GAAP.

 

(c)
Any deficiencies proposed as a result of any audits of the Company by any Governmental Entity have been paid or finally settled.

 

(d)
Neither the Company nor any Person acting for or on behalf of the Company has agreed to any extension or waiver that currently
is in effect of the statute of limitations applicable to any Tax Return of the Company with respect to any Taxes of the Company.

 

(e)
There are no present disputes as to Taxes payable by the Company, and the Company is not a party to any action or Proceeding by
any Governmental Entity for the collection or assessment of Taxes against or with respect to the Company. This Section 3.13(e)
does not apply to any Taxes or Tax Returns of any consolidated, combined, unitary or affiliated group.

 

For
the purposes of this Agreement, the representation and warranties contained in Section 3.8 and this Section
3.13 (the “Tax Representations”) shall constitute the exclusive representation and warranties
made by the Seller with respect to Taxes of the Company, and any consolidated, combined, unitary or affiliated Tax Return containing
any member of the Company or Seller shall be treated as outside the scope of this Agreement and all provisions in this Agreement
shall be deemed to exclude any such Tax Returns. No Tax Representation shall be deemed to apply directly or indirectly with respect
to any Post-Closing Tax Period, including, without limitation, as to the availability, with respect to any Tax, of any tax basis,
net operating loss carryovers, net capital loss carryovers, credits and similar Tax items of any Person.

 

Section
3.14  Affiliate Transactions. Except as set forth on Section 3.14 of
the Disclosure Schedules, there are no Contracts by and between the Company, on the one hand, and the Seller or any of its Affiliates,
on the other hand.

 

    24

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
 BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE
 THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

    

 

Article
IV

REPRESENTATIONS AND WARRANTIES OF SELLER

 

As
a material inducement to Buyer to enter into this Agreement and to consummate the Contemplated Transactions, except as set forth
in the Disclosure Schedules hereto, Seller hereby represents and warrants to Buyer, as of the Agreement Date and the Closing Date,
as follows:

 

Section
4.1 Organization, Qualification and Organizational Power.
Seller is a corporation duly incorporated, validly existing and in good standing under the Laws of the State of Delaware and has
all necessary power and authority to enter into this Agreement and the Transaction Documents to which it is a party, to carry
out its obligations hereunder and thereunder and to consummate the Contemplated Transactions. Seller is duly licensed or qualified
to do business and is in good standing in each jurisdiction in which the properties owned or leased by it or the operation of
its business makes such licensing or qualification necessary, except to the extent that the failure to be so licensed, qualified
or in good standing would not have a Material Adverse Effect.

 

Section
4.2 Authorization; Binding Effect. The execution and delivery
by Seller of this Agreement and the Transaction Documents to which it is a party, the performance by Seller of its obligations
hereunder and thereunder and the consummation by Seller of the Contemplated Transactions have been duly authorized by all requisite
action on the part of Seller. This Agreement has been, and upon their execution the Transaction Documents shall have been, duly
executed and delivered by Seller, and (assuming due authorization, execution and delivery by the other parties) this Agreement
constitutes, and upon their execution the Transaction Documents shall constitute, legal, valid and binding obligations of Seller
which are enforceable against Seller in accordance with their respective terms, subject to the Bankruptcy and Equity Exception.

 

Section
4.3 Approvals and Consents.

 

(a)
Except as set forth on Section 4.3(a) of the Disclosure Schedules and except as may be required by the HSR Act and
any other applicable Antitrust Laws, to the Knowledge of Seller, the execution, delivery and performance of this Agreement and
each Transaction Document by Seller does not and will not require any material consent, approval, authorization or other order
or declaration of, action by, filing with, notification to or permit from, any Governmental Entity, except as may be necessary
as a result of any facts or circumstances relating solely to Buyer or any of its Affiliates.

 

(b)
Assuming the making and obtaining of all filings, notifications, consents, approvals, authorizations and other actions referred
to in Section 4.3(a) and Section 4.3(a) of the Disclosure Schedules, and except as may result from
any facts or circumstances relating solely to Buyer, the execution, delivery and performance of this Agreement and the Transaction
Documents by Seller does not and will not (i) violate, conflict with or result in the breach of the organizational documents of
Seller, (ii) conflict with or violate any Law or Governmental Order applicable to Seller, or (iii) conflict with, result in any
breach of, constitute a default (or event which with the giving of notice or lapse of time, or both, would become a default) under,
require any consent under, or give to others any rights of termination, acceleration or cancellation of, any Contract to which
Seller is a party, except, in the case of clauses (ii) or (iii), as would not have a Material Adverse Effect.

 

    25

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
 BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE
 THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

    

 

Section
4.4 Brokerage. Seller does not have any liability or obligation
to pay any fees or commissions to any broker, finder, or agent with respect to the Contemplated Transactions for which Buyer or
any of its Affiliates could become liable or obligated.

 

Section
4.5 Investment Related Representations and Warranties.

 

(a)
The Buyer Shares will be acquired for investment for Seller’s own account, not as a nominee or agent, and not with a view
to the resale or distribution of any part thereof, and Seller has no present intention of selling, granting any participation
in, or otherwise distributing the same. By executing this Agreement, Seller further represents that Seller does not have any Contract,
undertaking, agreement or arrangement with any Person to sell, transfer or grant participations to such Person, with respect to
any of the Buyer Shares.

 

(b)
Seller is an “accredited investor” within the meaning of Rule 501(a) promulgated under the Securities Act of 1933,
as amended (the “Securities Act”), as presently in effect. Seller has substantial experience in evaluating
and investing in securities of companies and acknowledges that it has the capacity to protect its own interests in connection
therewith, can bear the economic risk of its investment and has such knowledge and experience in financial or business matters
that it is capable of evaluating the merits and risks of the investment in the Buyer Shares. Seller also represents it has not
been organized for the purpose of acquiring the Buyer Shares.

 

(c)
Seller acknowledges and understands that (i) the Buyer Shares issued pursuant to this Agreement will be issued in a transaction
exempt from registration under the Securities Act by reason of Section 4(a)(2) thereof and/or Regulation D promulgated under the
Securities Act and may not be re-offered or resold other than in conformity with the registration requirements of the Securities
Act and such other applicable rules and regulations or pursuant to an exemption therefrom, (ii) until the Buyer Shares have become
transferable pursuant to an exemption from such registration otherwise required thereunder, the Buyer Shares shall be characterized
as “restricted securities” under the federal securities laws inasmuch as they are being acquired from Buyer in a transaction
not involving a public offering, and (iii) under such laws and applicable regulations, such securities may be resold without registration
under the Securities Act only in certain limited circumstances.

 

(d)
Seller represents that it is familiar with Rule 144 under the Securities Act, as presently in effect, and understands the resale
limitations imposed thereby and by the Securities Act.

 

    26

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
 BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE
 THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

    

 

Article
V

REPRESENTATIONS AND WARRANTIES OF BUYER, MERGER SUB 1 AND MERGER SUB 2

 

As
a material inducement to Seller to enter into this Agreement and to consummate the Contemplated Transactions, except as set forth
on any disclosure schedule delivered by Buyer to Seller on the Agreement Date prior to execution of this Agreement, Buyer, Merger
Sub 1 and Merger Sub 2 hereby represent and warrant to Seller and the Company, as of the Agreement Date and the Closing Date,
as follows:

 

Section
5.1 Organization, Qualification and Organizational Power.
Each of Buyer, Merger Sub 1 and Merger Sub 2 is a legal entity duly organized, validly existing and in good standing under the
Laws of its jurisdiction of incorporation or formation, as applicable, and has all necessary power and authority to enter into
this Agreement and the Transaction Documents to which it is a party, to carry out its obligations hereunder and thereunder and
to consummate the Contemplated Transactions. Each of Buyer, Merger Sub 1 and Merger Sub 2 is duly licensed or qualified to do
business and is in good standing in each jurisdiction in which the properties owned or leased by it or the operation of its business
makes such licensing or qualification necessary, except to the extent that the failure to be so licensed, qualified or in good
standing would not have a Buyer Material Adverse Effect.

 

Section
5.2 Authorization; Binding Effect. The execution and delivery
by Buyer, Merger Sub 1 and Merger Sub 2 of this Agreement and the Transaction Documents to which each is a party, the performance
by them of their respective obligations hereunder and thereunder and the consummation by each of the Contemplated Transactions
have been duly authorized by all requisite action on the part of each of Buyer, Merger Sub 1 and Merger Sub 2. This Agreement
has been, and upon their execution the Transaction Documents shall have been, duly executed and delivered by Buyer, Merger Sub
1 and Merger Sub 2, and (assuming due authorization, execution and delivery by the other parties) this Agreement constitutes,
and upon their execution the Transaction Documents shall constitute, legal, valid and binding obligations of Buyer, Merger Sub
1 and Merger Sub 2 which are enforceable against Buyer, Merger Sub 1 and Merger Sub 2 in accordance with their respective terms,
subject to the Bankruptcy and Equity Exception.

 

Section
5.3 Approvals and Consents.

 

(a)
Except as set forth on Schedule 5.3(a) and except as may be required by the HSR Act and any other applicable Antitrust
Laws, to the Knowledge of Buyer, the execution, delivery and performance of this Agreement and each Transaction Document by Buyer,
Merger Sub 1 and Merger Sub 2 does not and will not require any material consent, approval, authorization or other order or declaration
of, action by, filing with, notification to or permit from, any Governmental Entity, except as may be necessary as a result of
any facts or circumstances relating solely to Seller, the Company or any of their respective Affiliates.

 

    27

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
 BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE
 THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

    

 

(b)
Assuming the making and obtaining of all filings, notifications, consents, approvals, authorizations and other actions referred
to in Section 5.3(a) and Schedule 5.3(a), and except as may result from any facts or circumstances
relating solely to Seller or the Company, the execution, delivery and performance of this Agreement and the Transaction Documents
by Buyer, Merger Sub 1 and Merger Sub 2 does not and will not (i) violate, conflict with or result in the breach of the organizational
documents of Buyer, (ii) conflict with or violate any Law or Governmental Order applicable to Buyer, Merger Sub 1 and Merger Sub
2, or (iii) conflict with, result in any breach of, constitute a default (or event which with the giving of notice or lapse of
time, or both, would become a default) under, require any consent under, or give to others any rights of termination, acceleration
or cancellation of, any Contract to which any of Buyer, Merger Sub 1 and Merger Sub 2 is a party except, in the case of clause
(ii) or (iii), as would not have a Buyer Material Adverse Effect.

 

Section
5.4 Brokerage. None of Buyer, Merger Sub 1 and Merger Sub
2 has any liability or obligation to pay any fees or commissions to any broker, finder, or agent with respect to the Contemplated
Transactions for which Seller, the Company or any of their respective Affiliates could become liable or obligated.

 

Section
5.5 Capitalization.

 

(a)
Schedule 5.5(a) sets forth a complete and accurate list of all issued and outstanding capital stock of each of Buyer,
Merger Sub 1 and Merger Sub 2, the holders thereof, the number and class of shares of capital stock of Buyer held by each such
holder, and the percentage interest in each of Buyer, Merger Sub 1 and Merger Sub 2 held by each such holder, as of the Agreement
Date. All capital stock of each of Buyer, Merger Sub 1 and Merger Sub 2 has been duly authorized and is validly issued, fully
paid and non-assessable and such capital stock has not been issued or transferred in violation of any Laws. Upon consummation
of the transactions contemplated by this Agreement, (i) Seller shall own all of the Buyer Shares, free and clear of all Liens
(except for restrictions on transfer under applicable securities laws or pursuant to the Shareholders’ Agreements), (ii)
the Buyer Shares shall constitute fifteen percent (15%) of the outstanding equity of Buyer, on a fully-diluted basis and after
giving effect to the issuance of all equity issued or issuable in respect of the Financing and the transactions described on Schedule
1.1, and (iii) the Buyer Shares shall have the same rights and preferences as the Series A Preferred Stock of Buyer to
be issued to the Investors and TNK Therapeutics, Inc., except that each Buyer Share shall have a corresponding CVR. At Closing,
after giving effect to the Contemplated Transactions (x) all of the Buyer Shares will have been duly authorized and validly issued,
fully paid and non-assessable and will not have been issued in violation of any Laws, and (y) none of the Buyer Shares will be
issued in violation of any agreement, arrangement or commitment to which Buyer is a party or is subject or in violation of any
preemptive or similar rights of any Person. The issuance of the Buyer Shares at Closing will not trigger any anti-dilution rights
or protections or adjustments to the conversion price of Buyer capital stock, and will be exempt from the registration provisions
of all applicable federal and state securities laws.

 

(b)
Except as set forth on Schedule 5.5(b), there are no outstanding subscriptions, options, rights, warrants, rights
of first refusal or offer, preemptive rights or other commitments of any character entitling any Person to purchase or otherwise
subscribe for or acquire any capital stock or equity interests of Buyer or any security convertible into or exchangeable for capital
stock or equity interests of Buyer, nor is there presently outstanding any security convertible into or exchangeable for capital
stock or equity interests of Buyer, nor has Buyer entered into any agreement with respect to any of the foregoing. Except as set
forth on Schedule 5.5(b), Buyer has no obligation to repurchase, redeem or otherwise acquire any capital stock or
voting interests in Buyer. Except as set forth on Schedule 5.5(b), there are no irrevocable proxies and no voting
agreements to which Buyer is a party with respect to any capital stock or other voting securities of Buyer and there are no voting
trusts, stockholder agreements, proxies or other agreements or understandings in effect with respect to the voting or transfer
of any of the capital stock of Buyer.

 

    28

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
 BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE
 THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

    

 

Section
5.6 Financing. Buyer has delivered to Seller a true and
complete copy of the Stock Purchase Agreement duly executed by each investor listed on the signature pages thereto (each, an “Investor”).
In order to capitalize the Buyer at Closing, pursuant to the Stock Purchase Agreement, the Investors have agreed to invest in
Buyer, subject to the terms and conditions set forth in the Stock Purchase Agreement, an aggregate amount equal to at least fifty
million dollars ($50,000,000) in exchange for Series A Preferred Stock of Buyer at a purchase price equal to the Closing Buyer
Share Price, and which aggregate investment amount is inclusive of the amount up to $10,000,000 contributed by Sorrento Therapeutics,
Inc. to Buyer under the Buyer Note or otherwise (the “Financing”). The Stock Purchase Agreement is in
full force and effect as of the Agreement Date.

 

Section
5.7 No Merger Sub Operations. Since formation, Merger Sub
1 has been treated for U.S. federal tax purposes as a corporation (within the meaning of the Code) and Merger Sub 2 has been treated
for U.S. federal tax purposes as an entity that is disregarded as an entity separate from its owner (within the meaning of Section
301.7701-3(b) of the U.S. Treasury regulations promulgated pursuant to the Code). Merger Sub 1 and Merger Sub 2 were formed solely
for the purpose of effecting the Mergers and have not engaged in any business activities or conducted any operations other than
in connection with the transactions contemplated hereby.

 

Section
5.8 Reorganization. Buyer does not have Knowledge of any
fact that could reasonably be expected to cause the transactions described in Section 2.1 and Section 2.2
to be treated as other than a tax-free “reorganization” under Section 368(a) of the Code.

 

Article
VI

COVENANTS

 

Section
6.1 Consents; Regulatory Filings.

 

(a)
Subject to the terms and conditions hereof, the Parties agree (without being obligated to make any payment to any third party
(other than payments to Governmental Entities in respect of the Governmental Permits or as a result of the other obligations of
the Parties pursuant to this Section 6.1)) to use their reasonable best efforts (except where a different standard
of efforts is required under this Section 6.1) to take, or cause to be taken, all actions and to do, or cause to
be done, all things necessary, proper or advisable to consummate and make effective as promptly as practicable the Contemplated
Transactions and to cooperate with the other Parties in connection with the foregoing, including using reasonable best efforts
(except where a different standard of efforts is required under this Section 6.1) to (i) obtain any necessary waivers,
consents and approvals from counter parties to Material Contracts or as otherwise set forth on Schedule 2.4(c)(ii)
(ii) obtain all consents, approvals and authorizations that are required to be obtained under any Law (including without limitation
in connection with the Governmental Permits) applicable to such Party and (iii) negotiate in good faith the Transaction Documents
(to the extent the form of such Transaction Document is not attached as an Exhibit to this Agreement).

 

    29

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
 BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE
 THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

    

 

(b)
Regulatory Filings. In addition to and not in limitation of the Company’s covenants contained in Section 6.1(a),
Buyer and Seller will, if determined by Buyer to be required, (i) make or cause to be made an appropriate filing of a Notification
and Report Form pursuant to the HSR Act with respect to the Contemplated Transactions as promptly as reasonably practicable and
advisable after the Agreement Date, and (ii) respond as promptly as practicable to inquiries or requests for information received
from the Federal Trade Commission, Department of Justice or any other Governmental Authority in connection with any such filings;
provided that Seller shall have no obligation to comply with a Request for Additional Information or Documentary Material
issued pursuant to 16 CFR § 803.20 (“Second Request”) and/or a subpoena or civil investigative
demand requesting documents and information similar to that usually demanded in a Second Request (“Compulsory Process
Request”). If the parties receive a Second Request or a Compulsory Process Request, then within fifteen (15) days
following receipt thereof, Seller shall notify Buyer in writing whether it intends to comply with such request, and if Seller
indicates that it does not intend to comply with such request, each of the parties shall be entitled to terminate this Agreement
in accordance with Section 8.1(g). If Seller indicates that it does intend to comply with such request, each of
the parties shall be obligated to comply with such request. Each of Buyer and the Company will cause all documents that it is
obligated to file with any Governmental Entity under this Section 6.1(b) to comply in all material respects with
all applicable Law. Neither Buyer nor Seller shall request early termination of the waiting period under the HSR Act.

 

(c)
Exchange of Information. Buyer, on the one hand, and Seller and the Company, on the other hand, will each promptly supply the
other with any information that is required in order to effectuate any filings or application contemplated by Section 6.1(a)
or Section 6.1(b). Subject to applicable Law relating to the exchange of information, and the preservation
of any applicable attorney-client privilege or work product doctrine, each of Seller and Buyer will use commercially reasonable
efforts to collaborate in reviewing and commenting on in advance, and to consult the other on, information relating to Seller,
the Company, Buyer or any of their Subsidiaries, that appears in any filing made with, or written materials submitted to, any
third party and/or any Governmental Entity in connection with any filing, investigation, or proceeding in connection with this
Agreement or the Contemplated Transactions (including under any Antitrust Law).

 

(d)
Cooperation. Each of the Parties agrees to use good faith efforts to (i) provide the other Parties reasonable advance notice of
all meetings with any Governmental Entity relating to any Antitrust Law and, unless prohibited by such Governmental Entity, afford
the other Parties (or their outside counsel) an opportunity to attend and participate in such meeting, (ii) to the extent practicable,
give the other Parties reasonable advance notice of all communications with any Governmental Entity relating to any Antitrust
Law, (iii) if any Governmental Entity initiates communication regarding any Antitrust Law, promptly notify the other Parties of
the substance of such communication, (iv) provide the other Parties with reasonable advance opportunity to review and comment
upon, and consider in good faith the views of the other Parties in connection with, all written communications with a Governmental
Entity regarding any Antitrust Law, and (v) promptly provide the other Parties (or their outside counsel) with copies of all written
communications to or from any Governmental Entity relating to any Antitrust Law, provided that such material may be redacted
as necessary to comply with contractual obligations, to preserve privilege or address good faith confidentiality concerns, or
to comply with applicable Laws.

 

    30

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
 BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE
 THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

    

 

(e)
Reasonable Efforts. In the event that Buyer, Seller or any of their Affiliates receives a Second Request and/or a Compulsory Process
Request, and Seller has notified Buyer in writing pursuant Section 6.1(b) that it intends to comply with such request,
then both parties shall be obligated to certify substantial compliance to the issuing agency pursuant to 15 § USC 18a no
later than 60 days prior to the Outside Date (which Outside Date the parties hereby agree to extend to a mutually acceptable date
as needed to comply with this sentence). For purposes of this paragraph, a party shall be deemed to have complied with a Second
Request and/or Compulsory Process Request, as applicable, by having provided a response that the party in good faith believes
to be in substantial compliance and by certifying its substantial compliance with the Second Request and/or Compulsory Process
Request, as applicable. If any Action is instituted (or threatened to be instituted) by any Governmental Entity or any third party
challenging any of the Contemplated Transactions, or which would otherwise prohibit or materially impair or materially delay such
Contemplated Transactions, each of Buyer, Seller and the Company will use commercially reasonable efforts to resolve any such
Actions so as to permit consummation of the Contemplated Transactions (and Seller and the Company will keep Buyer informed as
to the status of, and allow Buyer to participate in (but not control), such Actions. Notwithstanding anything herein to the contrary,
Buyer shall take, and shall cause its Affiliates to take, any and all unconditional and unqualified action necessary to obtain
any necessary approval or obtain the expiration of any waiting or suspension period under Antitrust Laws and to prevent the initiation
of any Action by any Governmental Entity under any Antitrust Laws or to prevent the entry of any Order that would otherwise make
the Contemplated Transactions unlawful, provided that none of Buyer, the Company or the Surviving Entity (or any of their
Affiliates) shall divest any assets or agree to any restrictions on its business (or the ability to own any portion of its business)
without Buyer’s prior written consent.

 

Section
6.2 Conduct of Business.

 

(a)
Except as may be otherwise contemplated by this Agreement or any Transaction Document, or as required by Law, from the Agreement
Date and prior to the Closing, without the prior written consent of Buyer (such consent not to be unreasonably withheld, conditioned
or delayed), the Company shall operate the Transferred Business in the ordinary course of business and consistent with past practice
and shall not (a) sell, transfer or otherwise dispose of any of the material assets of the Company, other than in the ordinary
course of business consistent with past practice, (b) amend or modify in any material respect any Material Contract, enter into
any Contract that would constitute a Material Contract (if entered into or adopted prior to the Agreement Date) or permit any
such Material Contract to be terminated (other than in the ordinary course of business or as mandated by the terms thereof as
in effect as of the Agreement Date), (c) suffer to exist, cause or permit any Lien upon the Shares or any material assets of the
Company, other than Permitted Liens, (d)(i) make any material Tax election (other than such elections that are consistent with
the most recent past practice of the Company), rescind or change any material Tax election, or adopt or change any method of accounting,
(ii) enter into any settlement of or compromise any material Tax liability, (iii) change any annual Tax accounting period, (iv)
enter into a closing agreement for any material amount of Tax, or (v) file any amended Tax Return or refund claim with respect
to any material Tax; or (e) act, or fail to act, in any way that could cause the transactions described in Section 2.1
and Section 2.2 not to qualify as a “plan of reorganization” under Section 368(a) of the Code.

 

    31

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
 BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE
 THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

    

 

(b)
Except as may be otherwise contemplated by this Agreement or any Transaction Document, or as required by Law, from the Agreement
Date and prior to the Closing, without the prior written consent of Seller (such consent not to be unreasonably withheld, conditioned
or delayed), Buyer will not, and will not permit any of its Affiliates to, except as set forth on Schedule 6.2(b),
consummate any transaction or take any action if the intent or reasonably anticipated consequence would be to prohibit, materially
delay or impair the parties from obtaining any approval or consent required as a condition to Closing under Section 7.1.

 

Section
6.3 Access and Certain Information. From the Agreement Date
through the Closing, the Company shall provide Buyer with reasonable access to such information as Buyer may from time to time
reasonably request with respect to the Transferred Business and the Contemplated Transactions, and shall provide Buyer and its
Representatives reasonable access during regular business hours and upon reasonable notice to the properties, books and records
of the Company pertaining to the Transferred Business as Buyer may from time to time reasonably request; provided, that
the Company shall not be required to provide any portions of its consolidated, combined or unitary Tax Return. Any disclosure
whatsoever during such investigation by Buyer shall not constitute any expansion of or additional representations or warranties
of Seller, the Company or any of their respective Affiliates beyond those specifically set forth in this Agreement. Notwithstanding
the foregoing, the Company shall not be required to disclose any information to Buyer if such disclosure would, in the Company’s
reasonable discretion (i) jeopardize any attorney-client or other legal privilege or (ii) contravene any applicable Laws, fiduciary
duty or binding agreement with any unrelated third party entered into prior to the Agreement Date; provided, that at the
request of Buyer and at Buyer’s sole cost and expense, the Company will cooperate with Buyer to obtain any consent or waiver
of a third party, or enter into protective arrangements if, in the Company’s reasonable discretion, obtaining such consent
or waiver or entering into such protective arrangements would enable the Company to disclose such information to Buyer without
contravening the foregoing clauses (i) or (ii) or otherwise adversely affecting Seller or the Company. When accessing any of Seller’s,
the Company’s or their respective Affiliates’ properties, Buyer and its authorized Representatives shall comply with
all of Seller’s or the Company’s, as applicable, safety and security requirements for the applicable property.

 

(a)
Buyer acknowledges and agrees that it is not authorized to and shall not (and shall not permit any of its Representatives or Affiliates
to), prior to the Closing, contact any employee (excluding executive officers), customer, supplier or distributor of, or other
Person with a material business relationship with, the Company or any of its Affiliates regarding the Company, the Transferred
Business or the Contemplated Transactions, in each case, without the Company’s prior written consent.

 

    32

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
 BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE
 THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

    

 

Section
6.4 Insurance Matters. From and after the Closing Date,
the Surviving Entity shall cease to be insured by Seller’s or it’s Affiliates’ insurance policies or by any
of their self-insured programs. For the avoidance of doubt, Seller and their respective Affiliates shall retain all rights to
control their respective insurance policies and programs, including the right to exhaust, settle, release, commute, buy-back or
otherwise resolve disputes with respect to any of such insurance policies and programs, notwithstanding whether any such policies
or programs would apply to any liabilities of Buyer.

 

Section
6.5 Cessation of Use of Seller’s Marks. None of Buyer
or any of its Affiliates shall have the right to use in any way any of the trademarks, service marks, Internet domain names, trade
names, trade dress, company names (including “Celgene” and “Celgene Cellular Therapeutics” and any derivative
thereof) or other identifiers of source or goodwill containing, incorporating or associated with any Intellectual Property of
Seller (“Seller’s Marks”), and from and after the Closing, Buyer shall cause the Surviving Entity
to immediately cease using Seller’s Marks.

 

Section
6.6 Employee Matters.

 

(a)
During the period commencing as of the Closing and ending on the first anniversary of the Closing Date, Buyer and its Affiliates
shall provide all employees of the Company immediately prior to the Closing Date (the “Company Employees”)
with (x) base salary, wages, and bonuses that are no less favorable than those in effect immediately prior to the Closing and
(y) other compensation (other than equity compensation) and employee benefits that are substantially similar in the aggregate
to those in effect immediately prior to the Closing.

 

(b)
With respect to the Company Employees, effective from and after the Closing Date, Buyer and its Affiliates (including the Surviving
Entity) shall (i) recognize, for all purposes under all plans, programs and arrangements established or maintained by Buyer or
its Affiliates (including the Surviving Entity) for the benefit of the Company Employees, service with Seller and its Affiliates
prior to the Closing Date to the extent such service was recognized under the corresponding plan covering such Company Employees
prior to the Closing Date, including for purposes of eligibility, vesting and benefit levels and accruals (other than with respect
to benefit accrual under a defined benefit pension plan or retiree medical plan), (ii) use commercially reasonable efforts to
waive any pre-existing condition exclusion, actively-at-work requirement or waiting period under all employee health and other
welfare benefit plans established or maintained by Buyer or its Affiliates (including the Surviving Entity) for the benefit of
the Company Employees, except to the extent such pre-existing condition, exclusion, requirement or waiting period was satisfied
or would not have applied to such individual under the corresponding plan covering such Company Employees prior to the Closing
Date, and (iii) to the extent permitted under the terms of the applicable plans, provide full credit for any co-payments, deductibles
or similar payments made or incurred prior to the Closing Date for the plan year in which the Closing Date occurs.

 

    33

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
 BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE
 THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

    

 

(c)
As of the Closing Date, Buyer or its Affiliates shall cover (or cause to be covered) each Company Employee under one or more defined
contribution plans and trusts intended to qualify under Section 401(a) of the Code, including any such plan containing a salary
deferral feature under Section 401(k) of the Code (collectively, the “Buyer DC Plan”). Buyer or its
Affiliates shall permit, and shall cause the Buyer DC Plan to accept, rollovers of account balances (including any outstanding
loans) with respect to Company Employees from Seller’s or its Affiliates’ defined contribution plans and trusts intended
to qualify under Section 401(a) of the Code.

 

(d)
Notwithstanding anything in this Section 6.6 to the contrary, nothing contained herein, whether express or implied,
shall be treated as an amendment or other modification of any employee benefit plan, program or arrangement maintained by any
of the Parties or any of their respective Affiliates, or shall limit the right of the Parties or any of their respective Affiliates
to amend, terminate or otherwise modify any employee benefit plan, program or arrangement maintained by such Party or any of its
Affiliates following the Closing Date. If (i) a Person other than any of the Parties makes a claim or takes other action to enforce
any provision in this Agreement as an amendment to any employee benefit plan, program or arrangement maintained by any of the
Parties or any of their respective Affiliates, and (ii) such provision is deemed to be an amendment to such employee benefit plan,
program or arrangement maintained by any of the Parties or any of their respective Affiliates even though not explicitly designated
as such in this Agreement, then, solely with respect to the employee benefit plan, program or arrangement maintained by any of
the Parties or any of their respective Affiliates at issue, such provision shall lapse retroactively and shall have no amendatory
effect with respect thereto. The Parties acknowledge and agree that all provisions contained in this Section 6.6
are included for the sole benefit of the Parties, and that nothing in this Agreement, whether express or implied, shall create
any third party beneficiary or other rights (i) in any other Person, including, without limitation, any employee or former employee
of Seller or its Affiliates (including the Company Employees), any participant in any employee benefit plan, program or arrangement
maintained by any of the Parties or any of their respective Affiliates, or any dependent or beneficiary thereof, or (ii) to continued
employment with any of the Parties or any of their respective Affiliates. Nothing in this Agreement shall affect the right of
the Parties or any of their respective Affiliates to terminate the employment of its employees.

 

Section
6.7 Public Announcements. No Party will issue or make any
press release or public statement with respect to this Agreement or the Contemplated Transactions without the prior written consent
of the other Party, except as may be required by Law; provided, that the Party proposing to issue a public announcement
or communication to satisfy a legal requirement shall provide the other Party with the text of such announcement or communication
reasonably prior to its issuance and consider in good faith comments provided by the other Party.

 

Section
6.8 Transaction Expenses. Except as otherwise set forth
herein, whether or not the Closing is consummated, all Seller Transaction Expenses shall be paid by the Seller and all Buyer Transaction
Expenses shall be paid by the Buyer.

 

Section
6.9 Further Assurances. The Parties agree (a) to furnish
upon request to each other such further information, (b) to execute and deliver to each other such other documents, and (c) to
do such other acts and things, all as the other Party may reasonably request for the purpose of carrying out the intent of this
Agreement and the Transaction Documents and the documents referred to herein and therein.

 

    34

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
 BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE
 THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

    

 

Section
6.10  Seller Assets; Surviving Entity Assets. If following the Closing, Buyer has
Knowledge that it possesses or has obtained any asset, property, Regulatory Approval or Intellectual Property that relates exclusively
to the BCMA CAR-T Program, the CAR-NK Program or the CTL Program (each, a “Seller Asset”), Buyer shall
promptly notify Seller thereof and shall cause the prompt transfer of such Seller Asset(s) to Seller for no additional consideration.
If following the Closing, Seller has Knowledge that it (or any of its Affiliates) possesses or has obtained any asset, property,
Regulatory Approval or Intellectual Property that relates primarily to the Transferred Business (each, a “Surviving
Entity Asset”), Seller shall promptly notify Buyer thereof and shall cause the prompt (unless a delay is contemplated
under the Transition Services Agreement) transfer of such Surviving Entity Asset(s) to the Surviving Entity for no additional
consideration.

 

Section
6.11  Financing Activities.

 

(a)
Buyer shall use its reasonable best efforts to cause the Financing to be consummated immediately prior to the Closing in order
to cause the condition to Closing in Section 7.3(e) to be satisfied. Buyer shall provide Seller with the opportunity
to review and comment on all documents or agreements (each, a “Financing Document”) to be executed by
Investors in connection with the Financing, and shall make such revisions to such Financing Documents as are reasonably requested
by Seller.

 

(b)
In order to cause the condition to Closing in Section 7.3(e) to be satisfied, promptly following the receipt by
Buyer of a duly executed Financing Document from an Investor, Buyer shall deliver a true and complete copy thereof to Seller.
Buyer shall not amend, modify or terminate any such Financing Document without Seller’s prior written consent. In the event
any Investor notifies Buyer of its intent to amend, modify or terminate any such Financing Document, Buyer shall promptly notify
Seller thereof.

 

(c)
In connection with the Financing, the Buyer shall obtain from each Investor and deliver to Seller a written representation and
acknowledgment, of which Seller and its Affiliates are express third party beneficiaries, that (i) any information of the Company
provided to such Investor, or to which such Investor has had access, in connection with the Financing (“Company Information”),
was provided to assist such Investor in making its own evaluation of Buyer, and an investment in Buyer, and was not, and does
not purport to be, or to contain all of the information that such Investor may consider material or desirable in making its decision
to invest in Buyer; (ii) such Investor has performed its own independent investigation and analysis of Buyer, and an investment
in Buyer without reliance on Seller or any of its Affiliates; (iii) such Investor is sophisticated and experienced in evaluating
companies like Buyer; (iv) the Company Information is not a substitute for such Investor’s independent evaluation and analysis
and has not been considered by such Investor as a recommendation by Seller or any of its Affiliates that such Investor invest
in Buyer; (v) the Company Information was provided to such Investor for informational purposes only; (vi) Seller and its Affiliates
bear no responsibility whatsoever (and shall not be liable in any respect) for the accuracy or completeness (or lack thereof)
of the Company Information or any information contained therein; (vii) neither Seller nor any of its Affiliates makes any representations
or warranties, express or implied, regarding the Company Information; (viii) neither Seller nor any of its Affiliates shall have
any liability to such Investor or any other person for furnishing the Company Information or for any action taken or decision
made by such Investor in purported reliance on the Company Information, including its decision to participate in or abstain from
investing in Buyer; and (ix) neither Seller nor any of its Affiliates shall have any liability to such Investor or any other person
for failing to furnish any other information at any time known to or in possession of Seller or any of its Affiliates or have
any obligation to update or supplement any of the Company Information or otherwise provide such Investor with any additional information.

 

    35

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
 BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE
 THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

    

 

Section
6.12  Buyer Acknowledgement. Buyer hereby acknowledges and agrees that:

 

(a)
The consummation of the transactions contemplated by this Agreement does not include the purchase and sale of any of the assets,
licenses or contracts used by the Seller in the provision of the services to be provided by it under the Transition Services Agreement.
The Surviving Entity will be granted a non-exclusive license to use such Intellectual Property pursuant to, and in accordance
with the terms and conditions of, the License Agreement.

 

(b)
The consummation of the transactions contemplated by this Agreement does not include purchase and sale of any Intellectual Property
that exclusively relates to the BCMA CAR-T Program, the CAR-NK Program or the CTL Program, all of which is owned by Seller, and
the Surviving Entity shall receive no license to the use thereof.

 

(c)
The Company does not own any Patents other than the Company Patents.

 

(d)
The consummation of the transactions contemplated by this Agreement does not include the purchase and sale of any of the equipment
listed on Schedule 6.12(d), all of which is owned solely by Seller and, from and after the Closing, the Surviving
Entity shall have no right to use such equipment.

 

Section
6.13  Transferred Intellectual Property Files. No less than sixty (60) days after
the Closing Date, Seller shall, and shall use its commercially reasonable efforts to cause any applicable Representatives to,
transfer to Buyer all prosecution files of Seller relating to the Company Intellectual Property, which prosecution files shall
not contain any communications or correspondence other than between the applicable applicants and patent offices, including such
files as are maintained by the Company’s and Seller’s intellectual property lawyers or agents; provided, however,
that (i) Seller shall inform Buyer of any filing deadlines in respect of the Patents included within the Company Intellectual
Property that will occur within three (3) months after the Closing Date prior to the Closing, and (ii) prior to the transfer of
such prosecution files to Buyer, Seller shall cooperate in good faith with Buyer to respond to Buyer’s reasonable requests
for information contained in such files.

 

Section
6.14  Transition Services Agreement. From and after the date hereof and prior to
the Closing, Buyer and Seller shall work together in good faith and shall use their respective reasonable best efforts to negotiate
a mutually acceptable Transition Services Agreement.

 

    36

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
 BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE
 THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

    

 

Article
VII

CONDITIONS TO THE CLOSING

 

Section
7.1 Conditions to Obligations of each of Buyer, Seller and the
Company to Closing. The respective obligations of each of Buyer, Seller and the Company to consummate the Contemplated Transactions
are subject to the satisfaction at or prior to the Closing Date of the following conditions, any of which may be waived in writing
by mutual agreement by the Parties (unless such waiver would be a violation of applicable Law):

 

(a)
No order. No Governmental Entity of competent jurisdiction shall have enacted, issued, promulgated, enforced or entered any non-appealable,
final and effective Law, injunction or other order which has the effect of making the Contemplated Transactions illegal or otherwise
prohibited.

 

(b)
Antitrust requirements. All requirements under Antitrust Laws reasonably determined to apply prior to the Closing in connection
with the Contemplated Transactions shall have been satisfied. Without limitation of the foregoing, the filings of Buyer and Seller
pursuant to the HSR Act, if any, shall have been made and the applicable waiting period and any extensions thereof shall have
expired or been terminated.

 

(c)
Governmental Entity Consents. The Parties shall have received all required consents, authorizations, orders and approvals from
Governmental Entities set forth on Sections 3.3(a) and 4.3(a) of the Disclosure Schedules, and Schedule
5.3(a), and no such consent, authorization, order or approval shall have been revoked.

 

(d) Third
Party Consents. The parties shall have received duly executed copies of the third party consents and approvals set forth on Schedule
2.4(c)(ii).

 

Section
7.2 Conditions to Buyer’s Obligation. Buyer’s
obligation to consummate the Contemplated Transactions at the Closing is subject to the satisfaction (or waiver by Buyer in its
sole discretion, it being understood that no such waiver shall waive any rights or remedies otherwise available to Buyer unless
explicitly waived) at or prior to the Closing Date of the following conditions precedent:

 

(a)
Representations and Warranties. The representations and warranties of Seller and the Company contained in Articles III
and IV that are qualified by materiality shall be true and correct on and as of the Closing Date as if made on and
as of such date (other than representations and warranties which address matters only as of a certain date which shall be true
and correct as of such certain date) and each of the representations and warranties that are not so qualified shall be true and
correct in all material respects on and as of the Closing Date as if made on and as of such date (other than representations and
warranties which address matters only as of a certain date which shall be true and correct in all material respects as of such
certain date), in each case, except where the failure to be true, individually or in the aggregate, has not resulted in or is
not reasonably expected to result in a Material Adverse Effect.

 

    37

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
 BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE
 THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

    

 

(b)
Compliance with Covenants. Seller, the Company and their respective Affiliates shall have performed or complied in all material
respects with all of the covenants and agreements required to be performed and complied with by them under this Agreement on or
prior to the Closing.

 

(c)
Document Deliveries. Buyer shall have received the documents that Seller is required to deliver or cause to be delivered pursuant
to Section 2.4(c).

 

(d)
No Material Adverse Effect. From the Agreement Date, there shall not have occurred any Material Adverse Effect, nor shall any
event or events have occurred that, individually or in the aggregate, with or without notice or lapse of time (or both) would
reasonably be expected to result in a Material Adverse Effect.

 

Section
7.3 Conditions to Seller’s and the Company’s Obligation.
Seller’s and the Company’s obligation to consummate the Contemplated Transactions at the Closing is subject to the
satisfaction (or waiver by Seller in its sole discretion, it being understood that no such waiver shall waive any rights or remedies
otherwise available to Seller unless explicitly waived) at or prior to the Closing Date of the following conditions precedent:

 

(a)
Representations and Warranties. The representations and warranties of Buyer, Merger Sub 1 and Merger Sub 2 contained in
Article V that are qualified by materiality shall be true and correct on and as of the Closing Date as if made on
and as of such date (other than representations and warranties which address matters only as of a certain date which shall be
true and correct as of such date) and the representations and warranties that are not so qualified shall be true and correct in
all material respects on and as of the Closing Date as if made on and as of such date (other than representations and warranties
which address matters only as of a certain date which shall be true and correct as of such date), in each case, except where the
failure to be true, individually or in the aggregate, has not resulted in or is not reasonably expected to result in a Buyer Material
Adverse Effect.

 

(b)
Compliance with Covenants. Buyer and its Affiliates shall have performed or complied in all material respects with all
of the covenants and agreements required to be performed and complied with by them under this Agreement on or prior to the Closing.

 

(c)
Document Deliveries and Consideration. Seller shall have received from Buyer the documents that Buyer is required to deliver
or cause to be delivered pursuant to Section 2.4(b), and the Buyer Shares as contemplated by Section 2.4(a).

 

(d)
Shareholders’ Agreements. Seller shall have received from Buyer a duly executed copy of each of the Shareholders’
Agreements, in form and substance reasonably satisfactory to Seller, which provide, inter alia, that, subject to the terms and
conditions of such Shareholder Agreements, (i) Seller will have the same rights as the Investors (including without limitation
pre-emptive and registration rights, if granted to the Investors), (ii) Seller will have the right to appoint an observer to the
board of directors of Buyer, (iii) Seller will have a right of first refusal to acquire the Surviving Entity on the same terms
and conditions as a bona fide third party if Buyer proposes to sell or transfer the Transferred Business or substantially all
of the assets of the Transferred Business to such third party, and (iv) Buyer will deliver to Seller all information reasonably
requested by Seller including without limitation annual unaudited financials within sixty (60) days following year-end and quarterly
financials within forty-five (45) days following quarter-end.

 

    38

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
 BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE
 THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

    

 

(e)
Financing. Seller shall have received from Buyer (i) evidence that the Financing has been consummated prior to the Closing
in form and substance reasonably satisfactory to Seller, and (ii) copies of Financing Documents and all other documents prepared
or executed by Buyer and/or any Investor in connection therewith.

 

(f)
No Buyer Material Adverse Effect. From the Agreement Date, there shall not have occurred any Buyer Material Adverse Effect,
nor shall any event or events have occurred that, individually or in the aggregate, with or without notice or lapse of time (or
both) would reasonably be expected to result in a Buyer Material Adverse Effect.

 

Article
VIII

TERMINATION

 

Section
8.1 Termination. This Agreement may be terminated at any
time prior to the Closing:

 

(a)
by the mutual written consent of Seller and Buyer;

 

(b)
by Buyer if, by September 1, 2017 (such date, or a later date agreed to in writing by Seller and Buyer (including pursuant to
Section 6.1(e)), the “Outside Date”), the conditions set forth in Sections 7.1
and 7.2 shall not have been satisfied, complied with or performed (unless such failure of satisfaction, compliance
or performance is the direct result of any action or failure to act on the part of Buyer and such action or failure constitutes
a material breach of this Agreement);

 

(c)
by Seller, if, by the Outside Date, the conditions set forth in Sections 7.1 and 7.3 shall not have
been satisfied, complied with or performed (unless such failure of satisfaction, compliance or performance is the result, directly
or indirectly, of any action or failure to act on the part of Seller or the Company and such action or failure constitutes a material
breach of this Agreement);

 

(d)
by Buyer, if Seller or the Company has materially breached or failed to comply with its warranties, representations or obligations
under this Agreement such that the conditions set forth in Section 7.2(a) or Section 7.2(b) would
not reasonably be expected to be satisfied, and such breach or failure to comply shall not have been cured within a period of
thirty (30) calendar days after Buyer shall have given written notice to Seller of such breach or failure to comply;

 

(e)
by Seller, if Buyer, Merger Sub 1 or Merger Sub 2 has materially breached or failed to comply with its warranties, representations
or obligations under this Agreement such that the conditions set forth in Section 7.3(a) or Section 7.3(b)
would not reasonably be expected to be satisfied, and such breach or failure to comply shall not have been cured within
a period of thirty (30) calendar days after Seller shall have given written notice to Buyer of such breach or failure to comply;

 

    39

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
 BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE
 THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

    

 

(f)
by either Buyer or Seller if any Governmental Entity having jurisdiction over a Party hereto shall have issued an order, decree
or ruling or taken any other action permanently enjoining, restraining or otherwise prohibiting the Contemplated Transactions
and such order, decree, ruling or other action shall have become final and nonappealable; provided, that the right to terminate
this Agreement pursuant to this Section 8.1(f) shall not be available to any Party whose breach of any provisions
of this Agreement has been the cause of, resulted in, or contributed to, such order, decree, ruling or other action; or

 

(g)
by either Buyer or Seller if Seller notifies Buyer that it does not intend to comply with any Second Request and/or Compulsory
Process Request in accordance with Section 6.1(b).

 

Section
8.2 Effect of Termination. Termination of this Agreement
pursuant to this Article VIII shall terminate all obligations of the Parties, except for the obligations under this
Section 8.2 or Section 10.1 hereof, provided, that nothing in this Section 8.2
shall relieve or limit the liability hereunder of any Party (the “Defaulting Party”) to another Party
on account of fraud or in connection with a willful and material breach of this Agreement by the Defaulting Party. For purposes
of this Agreement, a “willful and material breach” shall mean a material breach that is the consequence of an act
undertaken by the breaching party with the actual knowledge that the taking of such action would cause a breach.

 

Article
IX

INDEMNIFICATION

 

Section
9.1 Indemnification.

 

(a)
Subject to the limitations set forth in Section 9.3, from and after the Closing Date, Seller shall indemnify, defend
and hold harmless Buyer and its Affiliates and all of their respective officers, managers, directors, shareholders, members, Affiliates,
employees and agents (the “Buyer Indemnified Persons”) from and against any Losses actually suffered
or incurred by such Buyer Indemnified Persons arising out of or resulting from (i) any breach by Seller or the Company of any
representation or warranty of Seller or the Company contained in Article III or IV of this Agreement
or in any certificate delivered pursuant to Section 2.4(c)(iii), (ii) any failure by Seller to perform or comply
with any covenant of Seller in this Agreement, which requires performance by Seller after the Closing and, (iii) any Debt of the
Company that is unpaid as of the Closing or any unpaid Seller Transaction Expenses as of the Closing; provided, in each
case, that Buyer has submitted to Seller a Notice of Claim or Third Party Notice, as applicable, in respect thereof prior to the
date of expiration of the survival period specified in Section 9.3 (each a “Buyer Indemnification Claim”).

 

    40

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
 BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE
 THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

    

 

(b)
Subject to the limitations set forth in Section 9.3, from and after the Closing Date, Buyer shall indemnify, defend
and hold harmless Seller, its Affiliates and all of their respective officers, managers, directors, shareholders, members, Affiliates,
employees and agents (the “Seller Indemnified Persons”) from and against any Losses actually incurred
or suffered by such Seller Indemnified Persons arising out of or resulting from (i) any breach by Buyer, Merger Sub 1 or Merger
Sub 2 of any representation or warranty of Buyer, Merger Sub 1 or Merger Sub 2 contained in Article V of this Agreement
or in any certificate delivered pursuant to Section 2.4(b)(ii), (ii) any failure by Buyer or the Surviving Entity
to perform or comply with any covenant of Buyer or the Surviving Entity in this Agreement or in the CVR Agreement, which requires
performance after the Closing, (iii) any third party claim arising out of or resulting from the operation or ownership of the
Surviving Entity from and after the Closing, (iv) any third party claim arising out of or resulting from the Financing or any
of the transactions described on Schedule 1.1; and (v) any unpaid Buyer Transaction Expenses; provided, in
each case, that Seller has submitted to Buyer a Notice of Claim or Third Party Notice, as applicable, in respect thereof prior
to the date of expiration of the survival period specified in Section 9.3.

 

Section
9.2 Procedures for Indemnification.

 

(a)
If any Buyer Indemnified Person or Seller Indemnified Person (each an “Indemnified Person”) shall claim
indemnification hereunder for any claim (other than a third party claim) for which indemnification is provided in Section
9.1 above, Buyer (on behalf of a Buyer Indemnified Person) or Seller (on behalf of a Indemnified Person) shall promptly,
and in any event within fifteen (15) days after it first becomes aware of facts which give rise to the basis for such claim, give
written notice (a “Notice of Claim”) to Seller or Buyer, as applicable (each, an “Indemnifying
Person”), setting forth the basis for such claim or demand and the nature and preliminary estimated amount of the
claim, all in reasonable detail; provided, that no delay in providing such Notice of Claim will affect an Indemnified Person’s
rights hereunder except (and only then to the extent that) the Indemnifying Person is materially and adversely prejudiced thereby.
If an Indemnifying Person disputes any claim set forth in the Notice of Claim, it shall deliver to such Indemnified Person that
has given the Notice of Claim written notice indicating its dispute of such Notice of Claim (an “Objection Notice”)
within forty-five (45) days after the date the Notice of Claim is given (the “Response Period”). Following
the receipt of an Objection Notice during the Response Period, the Indemnified Person and the Indemnifying Person shall attempt
in good faith to agree upon the rights of the respective parties with respect to each of such claims in the Notice of Claim. If
the Indemnified Person and the Indemnifying Person should so agree, a memorandum setting forth such agreement shall be prepared
and signed by all Parties and the Indemnifying Person shall promptly pay such Losses as are set forth in such memorandum. If the
Indemnified Person and the Indemnifying Person are unable to resolve such dispute after good faith discussions within forty-five
(45) days (as may be extended by agreement of the Parties) following delivery of an Objection Notice, such dispute shall be resolved
by a court of competent jurisdiction in accordance with Section 11.5 hereof.

 

    41

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
 BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE
 THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

    

 

(b)
If an Indemnified Person shall claim indemnification hereunder arising from any claim or demand of a third party for which indemnification
is provided in Section 9.1 above (a “Third Party Claim”), the Indemnified Person shall
promptly, and in any event within fifteen (15) days after it first becomes aware of facts which give rise to the basis for such
Third Party Claim, give written notice (a “Third Party Notice”) to the Indemnifying Person, of the basis
for such claim or demand, setting forth the nature of the claim or demand in reasonable detail. The Indemnifying Person, upon
notice to the Indemnified Person within forty-five (45) days after receiving a Third Party Notice, shall have the right to assume
and control the defense of such Third Party Claim for which the Indemnifying Person is obligated to indemnify pursuant to this
Article IX at its own cost and through counsel of its choosing; provided, however, that the Indemnifying
Person shall not have the right to assume and control such defense: (i) if such Third Party Claim involves criminal allegations,
(ii) if outside counsel advises the Indemnified Person that there are conflicts of interest between the Indemnifying Person and
the Indemnified Person with respect to the Third Party Claim that cannot be waived, and/or (iii) if such Third Party Claim seeks
relief other than monetary damages (except where any non-monetary relief being sought is merely incidental to a primary claim
for monetary damages). The Indemnifying Person shall have the right to compromise and settle all indemnifiable matters related
to Third Party Claims which are susceptible to being settled, except to the extent that (i) such settlement would involve relief
other than monetary damages, or (ii) such settlement does not include an unconditional release of the Indemnified Person from
all liability in respect of such claim. The Indemnifying Person shall from time to time apprise the Indemnified Person of the
status of the claim, liability or expense and any resulting Action (including any enforcement Action) and shall furnish the Indemnified
Person with such documents and information filed or delivered in connection with such claim, liability or expense as the Indemnified
Person may reasonably request. The Indemnified Person shall not admit any liability to any third party in connection with any
matter which is the subject of a Third Party Notice and shall cooperate fully in the manner requested by the Indemnifying Person
in the defense of such claim. Notwithstanding anything herein stated, the Indemnified Person shall at all times have the right
to fully participate in such defense at its own expense directly or through counsel. If no notice of intent to defend is given
by the Indemnifying Person, the Indemnified Person shall, at the expense of the Indemnifying Person, undertake (with counsel selected
by the Indemnified Person and reasonably acceptable to the Indemnifying Person) the defense of such claim, liability or expense,
and shall have the right to compromise or settle such claim, liability or expense with the consent of the Indemnifying Person,
which consent shall not be unreasonably withheld, conditioned or delayed.

 

Section
9.3 Limitations on Indemnification.

 

(a)
All Fundamental Representations will survive the Closing until the expiration of the applicable statute of limitations, and the
representations and warranties of the Company in Section 3.13 (Taxes) shall survive as set forth in Section
10.8. All other representations and warranties under this Agreement shall survive the Closing until the 12 month anniversary
of the Closing Date. The covenants or other agreements contained in this Agreement shall survive the Closing in accordance with
their terms. Notwithstanding the foregoing, any indemnification claims asserted in good faith with reasonable specificity (to
the extent known at such time) and in writing by notice from the applicable Indemnified Person to the applicable Indemnifying
Person in accordance with this Article IX prior to the expiration date of the applicable statute of limitations
shall not thereafter be barred and such claims shall survive until finally resolved.

 

    42

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
 BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE
 THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

    

 

(b)
The amount of any Losses for which indemnification is provided for under this Agreement shall be reduced by (i) any amounts realizable
by the Indemnified Person as a result of any indemnification, contribution or other payment by any third party, (ii) any insurance
proceeds or other amounts realizable by the Indemnified Person from third parties with respect to such Losses and (iii) any Tax
benefit obtained by the Indemnified Person or its Affiliates in connection with the incurrence of the item for which indemnification
is due hereunder.

 

(c)
The Indemnified Person shall take all reasonable actions to timely make and diligently pursue any claims for insurance and/or
indemnification available from third parties with respect to Losses for which it will seek indemnification hereunder.

 

(d)
The Indemnifying Person shall be subrogated to the Indemnified Person’s rights of recovery to the extent of any Losses satisfied
by the Indemnifying Person. The Indemnified Person shall execute and deliver such instruments and papers as are necessary to assign
such rights and assist in the exercise thereof, including access to the books and records pertaining to the Transferred Business.

 

(e)
Notwithstanding anything to the contrary set forth in this Agreement, no Party shall have any obligation to indemnify any other
Party or their respective Indemnified Persons from and against consequential damages, special damages, incidental damages, indirect
damages, punitive damages, diminution in value or lost profits.

 

(f)
With respect to any claim for indemnification by a Buyer Indemnified Person under this Article IX that has become
Finally Determined, Seller shall have the option, in its sole discretion, to satisfy any Losses for which such Buyer Indemnified
Person is entitled to indemnification hereunder in respect of such claim by paying the aggregate dollar amount of such Losses,
or any portion thereof, in cash and/or surrendering to Buyer such number of Buyer Shares issued to Seller as is equal to: (x)
the aggregate dollar amount of such Losses, or any portion thereof, divided by (y) the Value of one Buyer Share. Seller
shall notify Buyer as to whether it elects to satisfy its indemnification obligation by paying cash and/or surrendering Buyer
Shares within thirty (30) days of the date that the applicable claim for indemnification has become Finally Determined. If Seller
fails to so notify Buyer within such thirty (30) day period, Buyer shall have the right to cancel such number of Buyer Shares
issued to Seller as is equal to: (x) the aggregate dollar amount of the Losses for which a Buyer Indemnified Person is entitled
to indemnification in respect of such Finally Determined claim, divided by (y) the Value of one Buyer Share. A claim for
indemnification pursuant to this Article IX shall be “Finally Determined” when the parties
to such claim have so determined, by mutual written agreement, the outcome of such claim or, if disputed, when a final and non-appealable
Governmental Order of a court of competent jurisdiction shall have been entered concerning such matters after following the procedures
set forth in this Agreement. For purposes of this Article IX, “Value” shall mean the greater
of (1) the Closing Buyer Share Price, and (2) the value of one Buyer Share based on the fair market value of Buyer, calculated
as of the date that such payment is to be made to a Buyer Indemnified Person for such Loss, with such determination of fair market
value to be made in good faith by mutual agreement of Buyer and Seller; provided, however, that if Buyer and Seller cannot
mutually agree on the fair market value of Buyer, then Buyer and Seller shall mutually agree upon an independent third party valuation
firm, which shall be instructed to make a determination of the fair market value of Buyer as if all of Buyer’s equity were
being sold in a single transaction, assuming a willing buyer and a willing seller, to the highest bidder pursuant to a competitive
auction process where the objective is to obtain the highest price reasonably obtainable for Buyer as a whole (without liquidity
or marketability or minority discounts). The determination by the independent third party valuation firm will be made within ten
(10) Business Days after its retention and will be final and binding upon the parties; provided, however, that in no event
shall the Value of one Buyer Share based on the fair market value of Buyer as determined by the independent valuation firm be
lower than the Closing Buyer Share Price. The fees, costs and expenses of the independent third party valuation firm will be borne
by Seller.

 

    43

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
 BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE
 THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

    

 

(g)
After the Closing, the indemnification provided in this Article IX (including all limitations contained herein)
shall (except as described in Article X) be the sole and exclusive remedy for all matters relating to this Agreement,
and for the breach of any representation, warranty, covenant or agreement contained herein or in any certificate delivered hereunder;
provided, however, that (i) the foregoing shall not apply in the case of claims based solely upon the actual fraud, fraudulent
misrepresentation or fraudulent misconduct of a Party hereto, and (ii) no Party shall be prohibited from seeking any equitable
relief available to it pursuant to this Agreement with respect to any failure by another Party to perform any covenant of it contained
in this Agreement. Except in the case of actual fraud, fraudulent misrepresentation or fraudulent misconduct by Seller or the
Company, (x) the Buyer Indemnified Persons shall seek recovery of Losses hereunder solely from, and the Buyer Indemnified Persons
sole and exclusive recourse for all such Losses shall be limited to, the Buyer Shares, and (y) in the event that Seller surrenders
all of the Buyer Shares to Buyer in accordance with this Article IX, Seller shall have no further obligation to
indemnify the Buyer Indemnified Persons hereunder.

 

(h)
Notwithstanding anything to the contrary contained in this Article IX:

 

(i)
The procedural provisions of Article X shall govern all claims for indemnification of Taxes and associated expenses;
and

 

(i)
For the avoidance of doubt, if an Indemnified Person is entitled to indemnification under more than one provision of Section
9.1 and/or Article X, as applicable, such Indemnified Person may assert a claim under any applicable provision;
provided, however, that such Indemnified Person may not recover, and the Indemnifying Person shall not be required to indemnify
the Indemnified Person, more than once in respect of the same Loss.

 

(ii)
Notwithstanding anything contained herein to the contrary, the limitations on indemnification in this Section 9.3
shall not apply in the case of actual fraud, fraudulent misrepresentation or fraudulent misconduct by any Party.

 

(j)
Notwithstanding anything to the contrary set forth in this Section 9.3, except in the case of actual fraud, fraudulent
misrepresentation or fraudulent misconduct by Seller or the Company or breach of any Seller Fundamental Representation, Seller
shall have no liability with respect to any claim for indemnification pursuant to Section 9.1(a)(i) (i) unless and
until the aggregate amount of all Losses for which Seller would, but for this clause, be liable pursuant to Section 9.1(a)(i),
exceed on a cumulative basis $1,500,000 (the “Deductible”), in which case Seller shall be liable only
for such Losses in excess of the Deductible, and (ii) for any individual or series of related Losses which do not exceed $150,000
(which Losses shall not be counted toward the Deductible).

 

    44

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
 BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE
 THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

    

 

(k)
Except in the case of actual fraud, fraudulent misrepresentation or fraudulent misconduct by Seller or the Company or breach of
any Seller Fundamental Representation, under no circumstance shall the aggregate amount of all Losses for which Seller is liable
for indemnification pursuant to Section 9.1(a)(i) exceed $10,000,000. Except in the case of actual fraud, fraudulent
misrepresentation or fraudulent misconduct by Seller or the Company, under no circumstances shall the aggregate amount of all
Losses for which Seller is liable hereunder exceed, in the aggregate, the Buyer Shares.

 

(l)
Except in the case of actual fraud, fraudulent misrepresentation or fraudulent misconduct by Buyer, Merger Sub 1 or Merger Sub
2, under no circumstance shall the aggregate amount of all Losses for which Buyer is liable hereunder exceed, in the aggregate,
the aggregate Value of the Buyer Shares.

 

Section
9.4 Effect of Knowledge. Notwithstanding anything herein
to the contrary, Seller shall not be liable under this Article IX for any Losses based upon or arising out of any
inaccuracy in, breach of, or failure to comply with any representation, warranty, covenant or agreement of Seller or the Company
contained in this Agreement if Buyer had Knowledge of such inaccuracy, breach or failure to comply prior to the Closing.

 

Article
X

TAX MATTERS

 

Section
10.1  Tax Indemnity.

 

(a)
Seller shall indemnify and hold harmless Buyer from and against any and all liabilities for Taxes imposed on the Company or the
Surviving Entity for Pre-Closing Tax Periods. Notwithstanding anything to the contrary in this Agreement, Seller shall not be
required to indemnify or hold harmless Buyer for any liabilities for (x) Taxes resulting from, or attributable to, any transaction
or action undertaken by Buyer after the Closing on the Closing Date and which is outside of the ordinary course of business, or
(y) any Tax liability attributable to a Pre-Closing Tax Period triggered by an election made by Buyer after the Closing. For the
avoidance of doubt, no indemnification is provided by Seller under this Section 10.1 with respect to the amount
of any Tax attributes (including losses, deductions, credits and tax basis) that carry forward from a Pre-Closing Tax Period to
a Post-Closing Tax Period.

 

(b)
Buyer shall indemnify and hold harmless Seller from and against any and all liabilities for Taxes of the Surviving Entity for
Post-Closing Tax Periods.

 

(c)
Except as otherwise provided in Section 9.3(g), Seller shall pay to Buyer any amount of cash required to be paid
by it pursuant to Section 10.1(a). Buyer shall pay to Seller any amount required to be paid by it pursuant to Section
10.1(b), within the later of (x) ten (10) days after of cash Buyer receives written notice from Seller under Section
10.1 requesting such payment, and (y) thirty (30) days prior to the date that the indemnified Tax or expense is required
to be paid.

 

    45

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
 BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE
 THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

    

 

(d)
The amount of any indemnity pursuant to this Section 10.1 shall be determined net of any Tax benefits obtained by
the indemnitee or its Affiliates in connection with the incurrence of the item for which indemnification is due hereunder. Any
payments made by Seller or Buyer under this Article X or Section 9.1 are intended by the Parties to
this Agreement to be treated for U.S. federal and applicable state and local income tax purposes as an adjustment to the purchase
price and, except as otherwise required by applicable Law, the Parties shall not take any position on any Tax Return or otherwise
that is inconsistent with such intention.

 

Section
10.2  Filing and Payment Responsibility.

 

(a)
Seller shall timely prepare and file, or cause to be timely prepared and filed, all Tax Returns for the Company for a Pre-Closing
Tax Period (other than a Pre-Closing Tax Period included in a Straddle Period), and such Tax Returns shall be prepared in a manner
consistent with applicable Law and past practices with respect to the Company. Seller shall provide each such Tax Return to Buyer
no less than fifteen (15) days prior to the due date for filing such Tax Return (including extensions, with Buyer (at Seller’s
expense and direction) to apply for any extensions). Buyer shall sign and timely file, or cause to be signed and timely filed,
all Tax Returns referenced in the prior sentence, or shall timely provide Seller with the necessary authorizations to sign and
to file such Tax Returns.

 

(b)
Seller shall timely prepare and file, or cause to be timely prepared and filed, all Tax Returns of the Company for all Straddle
Periods, and such Tax Returns shall be prepared in a manner consistent with applicable Law and past practices with respect to
the Company. Seller shall provide, or cause to be provided, to Buyer a copy of each such Tax Return at least thirty (30) days
prior to the due date for filing such Tax Return (including extensions) for Buyer’s review and comment. Seller shall consider
in good faith all reasonable comments of Buyer with respect to such Tax Returns, and shall make such revisions to such Tax Returns
as are reasonably requested by Buyer to the extent that such revisions relate solely to Taxes of any Post-Closing Tax Period.

 

(c)
Each Party that files a Tax Return of the Company (or the Surviving Entity) after the Closing pursuant to Section 10.2(a)
or (b) shall provide such other Party with a copy of such Tax Return no later than ten (10) days after the filing of each
such Tax Return.

 

(d)
Not less than two (2) Business Days prior to the due date (with regard to any applicable extensions) of any Tax Return referred
to in Section 10.2(a) or Section 10.2(b), Seller shall provide Buyer with the funds to timely pay
the Tax liability due and attributable to the Pre-Closing Tax Period with respect to each such Tax Return.

 

(e)
In the event applicable Law does not require or permit the Parties to close a Tax periods as of the Closing Date, the allocation
of Tax liability between the Pre-Closing Tax Period and the Post-Closing Tax Period comprising a Straddle Period shall be made
in accordance with this Section 10.2(e) as follows:

 

    46

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
 BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE
 THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

    

 

(i)
in the case of Taxes based upon income, gross receipts (such as sales Taxes) or specific transactions involving Taxes other than
Taxes based upon income or gross receipts, the amount of Taxes attributable to any Pre-Closing Tax Period or Post-Closing Tax
Period included in the Straddle Period shall be determined by closing the books of the Company as of the close of the Closing
Date and by treating each of such Pre-Closing Tax Period and Post-Closing Tax Period as a separate taxable year; and

 

(ii)
in the case of any other Taxes, (x) the amount of Taxes attributable to any Pre-Closing Tax Period included in the Straddle Period
shall be equal to the amount of such Taxes for the Straddle Period multiplied by a fraction, the numerator of which is the number
of days in the Pre-Closing Tax Period included in the Straddle Period and the denominator of which is the total number of days
in the Straddle Period, and (y) the amount of such Taxes attributable to any Post-Closing Tax Period included in a Straddle Period
shall be the excess of the amount of the Taxes for the Straddle Period over the amount of Taxes attributable to the Pre-Closing
Tax Period included in such Straddle Period.

 

Section
10.3  Tax Refunds. Any refund of Taxes of the Company (including any interest paid
thereon) for Pre-Closing Tax Periods received by the Company, received by Buyer or its Affiliates with respect to the Company,
or credited against the Tax liability of the Company, Buyer or its Affiliates, shall be for the benefit of Seller, and Buyer shall,
or shall cause the Surviving Entity or its Affiliates, as applicable, to, pay to Seller any such refund promptly upon receipt
or credit thereof. Seller shall have the right, at its expense, to request that Buyer pursue any such refund that may be obtained
by filing IRS Form 4466 (or by any similar form or procedure of any other Tax authority). In addition, if the aggregate payments
of estimated taxes made by, or on behalf of, the Company before the Closing for any Straddle Period exceed the Tax liability of
the Company for the Pre-Closing Tax Period included in such Straddle Period, Buyer shall pay, or cause to be paid, such excess
amount to Seller promptly upon receiving the benefit of such excess amount (through a reduction of any Tax payment required to
be made by the Company or by Buyer or its Affiliates for Post-Closing Tax Periods).

 

Section
10.4  Audits. Buyer shall promptly notify Seller in writing upon receipt by Buyer
or its Affiliates (including the Surviving Entity) of notice of any pending or threatened Tax audit or assessment which could
affect the indemnification obligations of Seller in respect of any Pre-Closing Tax Period. Subject to Section 10.4(b),
Seller shall have the sole right, at its expense, to represent the interests of the Company and to employ counsel of their choice
in any Tax Proceeding relating to Pre-Closing Tax Periods (other than a Tax Proceeding involving a Straddle Period), by notifying
Buyer in writing within thirty (30) days from its receipt from Buyer of the notice described in the first sentence of this Section
10.4(a) of its intention to assume control of the conduct of such Tax Proceeding. Buyer shall be entitled (at its expense)
to attend such Tax Proceeding (whether such Tax Proceeding is conducted in person, by telephone or otherwise) with its representatives
and to receive copies of all written communications, materials and submissions related to such Tax Proceeding received from, or
provided to, the Governmental Entity and Seller shall keep Buyer informed on a timely basis of all developments. For the avoidance
of doubt, the Parties agree and acknowledge that this Section 10.4(a) shall not apply to a Tax Proceeding regarding
Tax Returns of the combined, consolidated, or unitary group that includes the Company and for which Seller is the parent corporation.
In the event a Tax Proceeding involves Pre-Closing Tax Periods and Post-Closing Tax Periods and the parties are not able to separate
the periods into separate Tax Proceedings, Seller and Buyer shall jointly control the conduct and resolution of such Tax Proceeding
or portion thereof; provided, however, if any issue in such Tax Proceeding affects exclusively (i) Pre-Closing Tax Periods,
then the procedures of Section 10.4(a) shall apply with respect to such issue and/or (ii) Post-Closing Tax Periods,
then Buyer shall have the right to control such Tax Proceeding with respect to such issue. Each Party shall be entitled to employ
counsel of its choice at its own expense. For the avoidance of doubt, the Parties agree and acknowledge that this Section
10.4(b) shall not apply to a Tax Proceeding regarding Tax Returns of the combined, consolidated, or unitary group that
includes the Company and for which Seller is the parent corporation.

 

    47

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
 BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE
 THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

    

 

(a)
Except as otherwise provided in Section 10.5(b), Buyer shall have the right, with counsel of its choice at Buyer’s
expense, to represent the interests of the Surviving Entity in any Tax Proceeding involving a Straddle Period of the Company.
Seller may participate in any such Tax Proceeding at its own expense and Seller shall be kept informed of the progress of such
Tax Proceeding. Seller’s consent shall be required prior to the settlement of any Tax Proceeding relating to a Straddle
Period, which consent shall not be unreasonably withheld, conditioned or delayed. For the avoidance of doubt, the Parties agree
and acknowledge that this Section 10.4(c) shall not apply to a Tax Proceeding regarding Tax Returns of the combined,
consolidated, or unitary group that includes the Company and for which Seller is the parent corporation.

 

Section
10.5  Cooperation. After the Closing, Buyer and Seller shall (a) cooperate and provide
each other with such information relating to the Company as the other Party may reasonably request in (i) preparing or filing
any Tax Return, (ii) the claiming of any Tax refund for the account of Seller in accordance with Section 10.3, or
(iii) conducting or defending any Tax Proceeding with respect to a Pre-Closing Tax Period, and (b) retain any records related
to Taxes of the Company for a Pre-Closing Tax Period until the seventh (7th) anniversary of the Closing; provided, however,
that Seller shall not be required to deliver any Tax Returns that are Tax Returns of the combined, consolidated, or unitary group
that includes the Company and for which Seller is a member.

 

Section
10.6  Coordination with Other Provisions. Notwithstanding anything in this Agreement
to the contrary, (a) Section 10.1 shall constitute the sole source of indemnification rights under this Agreement
for Taxes and associated expenses of the kind described thereunder, and (b) the procedural provisions of this Article X
shall govern all claims for indemnification of such Taxes and associated expenses.

 

Section
10.7  Transfer Taxes. Each of Buyer and Seller shall assume liability for and pay
fifty percent (50%) of all Transfer Taxes arising out of or in connection with the transactions effected pursuant to this Agreement
as well as all out-of-pocket expenses associated with the preparation and filing of the Tax Returns under this Section 10.7.
The Party required to file any Tax Returns relating to Transfers Taxes shall timely file or cause to be filed all necessary documentation
and any such Tax Returns.

 

Section
10.8  Period of Limitation. Any claim for a breach of Section 3.13
(Taxes) or for indemnification for Taxes under this Article X shall be brought prior to two (2) years from the Agreement
Date; otherwise the Person bringing the claim (and its Affiliates) shall have no rights to indemnification under this Agreement.

 

    48

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
 BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE
 THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

    

 

Section
10.9  Amended Returns. Buyer shall not file, or cause to be filed, any amended Tax
Return or Tax refund claim with respect to any Pre-Closing Tax Period without Seller’s written consent, which consent shall
not be unreasonably withheld, conditioned, or delayed.

 

Section
10.10 Loss and Tax Attribute Carrybacks. Buyer shall not cause any loss or other Tax attribute to be carried
back to a Pre-Closing Tax Period, except as otherwise required by Law.

 

Section
10.11 Closing Date Activities. Buyer agrees not to engage, and not to cause or permit Surviving Entity to
engage, in any transaction or action outside of the ordinary course of business after the Closing on the Closing Date.

 

Section
10.12 338(g) Election. Notwithstanding anything herein to the contrary, Buyer shall not make any election pursuant to Section
338(g) of the Code with respect to the Company.

 

Section
10.12 Consolidated Group Tax Matters. Notwithstanding anything herein to the contrary, (i) Seller and the Company shall
not be required to provide Buyer with access to, or copies of, any consolidated, combined, unitary or affiliated Tax Return, except
any such Tax Return that only includes the Company and its Subsidiaries, (ii) Seller shall have sole control over the filing of
such Tax Returns, and (iii) all such Tax Returns shall be treated as outside the scope of this Agreement and all provisions in
this Agreement shall be deemed to exclude any such Tax Returns.

 

Article
XI

MISCELLANEOUS

 

Section
11.1  Confidentiality. Except for disclosures expressly permitted pursuant to Section
6.7, each Party agrees that it will not, and will cause its Representatives not to, use any information obtained pursuant
to Section 6.3 (as well as any other information obtained in connection with the entering into of this Agreement)
for any purpose unrelated to the Contemplated Transactions. Subject to the requirements of applicable Law, each Party will keep
confidential, and will cause its Representatives to keep confidential, all information and documents obtained pursuant to Section
6.3 (as well as any other information obtained in connection with the entering into of this Agreement) unless such information
(i) was already known to such Party on a non-confidential basis and other than as a result of a breach of a confidentiality obligation
by any Person, (ii) becomes available to such Party from other sources not bound by a confidentiality obligation and who learn
such information other than as a result of a breach of a confidentiality obligation by any Person, (iii) is disclosed with the
prior written approval of the Party to which such information pertains or (iv) is or becomes readily ascertainable from published
information or trade sources other than as a result of the wrongful act of any Person. In the event that this Agreement is terminated
or the Contemplated Transactions shall otherwise fail to be consummated, each Party shall promptly cause all copies of documents
or extracts thereof containing information and data as to another Party hereto to be destroyed (in which case such Party shall
furnish a certificate of destruction to the other Party) or returned to the Party which furnished the same, except as required
by applicable Law, regulation or document retention policies. Seller’s obligations under this Section 11.1
shall terminate immediately following the Closing. No investigation pursuant to this Section 11.1 or information
provided or received by any Party hereto pursuant to this Agreement will affect any of the representations or warranties of the
Parties hereto contained in this Agreement or the conditions hereunder to the obligations of the Parties hereto.

 

    49

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
 BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE
 THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

    

 

Section
11.2  Consent to Amendments; Waiver. This Agreement may be amended or modified, in
each case upon the approval, in writing, executed by each of the Parties. Each Party to this Agreement may: (a) extend the time
for the performance of any of the obligations or other acts of the other Parties; (b) waive any inaccuracies in the representations
and warranties of the other Parties contained herein or in any document delivered by the other Party or Parties pursuant hereto
or (c) waive compliance with any of the agreements of the other Parties or conditions to such Parties’ obligations contained
herein. Any such extension or waiver will be valid only if set forth in an instrument in writing signed by the Party to be bound
thereby.

 

Section
11.3  Entire Agreement. This Agreement, including the Schedules attached hereto,
and the other agreements referred to herein constitute the entire agreement among the Parties with respect to the matters covered
hereby and supersede all previous written, oral or implied understandings among them with respect to such matters.

 

Section
11.4  Successors and Assigns. Except as otherwise expressly provided in this Agreement,
neither this Agreement nor any of the rights, interests or obligations hereunder may be assigned by any Party without the prior
written consent of the other Parties. All covenants and agreements set forth in this Agreement by or on behalf of the Parties
shall bind and inure to the benefit of the respective successors and permitted assigns of the Parties, whether so expressed or
not.

 

Section
11.5  Governing Law; Consent to Jurisdiction; Venue; Waiver of Jury Trial. THIS AGREEMENT
WILL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE DOMESTIC LAWS OF THE STATE OF DELAWARE FOR CONTRACTS ENTERED INTO AND
TO BE PERFORMED IN SUCH STATE WITHOUT GIVING EFFECT TO ANY CHOICE OR CONFLICT OF LAW PROVISION OR RULE (WHETHER OF THE STATE OF
DELAWARE OR ANY OTHER JURISDICTION) THAT WOULD CAUSE THE APPLICATION OF THE LAWS OF ANY JURISDICTION OTHER THAN THE STATE OF DELAWARE.
EACH PARTY HERETO HEREBY SUBMITS TO THE EXCLUSIVE JURISDICTION OF THE UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF
NEW YORK AND OF ANY NEW YORK STATE COURT SITTING IN NEW YORK, NEW YORK FOR PURPOSES OF ALL LEGAL PROCEEDINGS ARISING OUT OF OR
RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY AND AGREES THAT PROCESS SHALL BE SERVED UPON SUCH PARTY IN
THE MANNER SET FORTH IN SECTION 11.6, AND THAT SERVICE IN SUCH MANNER SHALL CONSTITUTE VALID AND SUFFICIENT SERVICE OF PROCESS.
EACH PARTY HERETO IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY LAW, ANY OBJECTION WHICH IT MAY NOW OR HEREAFTER HAVE
TO THE LAYING OF THE VENUE OF ANY SUCH PROCEEDING BROUGHT IN SUCH A COURT AND ANY CLAIM THAT ANY SUCH PROCEEDING BROUGHT IN SUCH
A COURT HAS BEEN BROUGHT IN AN INCONVENIENT FORUM. EACH PARTY HERETO HEREBY IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY
IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.

 

    50

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
 BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE
 THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

    

 

Section
11.6  Notices. All notices and other communications given or made pursuant hereto
shall be in writing and shall be deemed to have been duly given or made (a) as of the date delivered, if delivered personally,
prior to 5:00 p.m. local time, (b) on the date the delivering party receives confirmation, if delivered by facsimile or electronic
transmission, prior to 5:00 p.m. local time, (c) three (3) Business Days after being mailed by registered or certified mail (postage
prepaid, return receipt requested) or (d) one (1) Business Day after being sent by overnight courier (providing proof of delivery),
to the Parties at the following addresses (or at such other address for a Party as shall be specified in a notice given in accordance
with this Section 11.6):

 

If
to Seller, to:

 

c/o
Celgene Corporation

86
Morris Avenue

Summit,
New Jersey 07901

Facsimile:
[***]

Attention:
[***]

 

with
copies, which shall not constitute notice to Seller, to:

 

Proskauer
Rose LLP

Eleven
Times Square

New
York, New York 10036

Facsimile:
[***]

Attention:
[***.]

 

If
to Buyer, to:

 

Celularity
Inc.

7
Powder Horn Drive

Warren,
New Jersey 07059

Telephone
No.: [***]

Email:
[***]

Attention:
[***]

 

with
a copy, which shall not constitute notice to Buyer, to:

 

Jones
Day

4655
Executive Drive, Suite 1500

San
Diego, CA 92121

Facsimile:
[***]

Attention:
[***]

 

    51

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
 BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE
 THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

    

 

Section
11.7  Schedules; Disclosure Schedules. The Schedules to this Agreement constitute
a part of this Agreement and are incorporated into this Agreement for all purposes as if fully set forth herein. Any information
disclosed in any section or subsection of the Disclosure Schedules shall be deemed to be disclosed for purposes of the corresponding
section or subsection of this Agreement and no information disclosed in any particular section nor subsection of the Disclosure
Schedules shall be deemed to be disclosed for purposes of any other section or subsection of this Agreement in this Agreement
unless (a) expressly made therein (by cross-reference or otherwise) or (b) it is reasonably apparent on the face of such disclosure
that such disclosure is applicable to such other sections or subsections of this Agreement. The disclosure of any item or matter
in any Schedule hereto shall not be taken as an indication of the materiality thereof or the level of materiality that is applicable
to any representation or warranty set forth herein. Without limiting the foregoing, no such reference to or disclosure of a possible
breach or violation of any Contract, Law or Governmental Order shall be construed as an admission or indication that a breach
or violation exists or has actually occurred.

 

Section
11.8  Counterparts. This Agreement may be executed in counterparts, all of which
taken together shall constitute one agreement. For purposes of this Agreement, signatures delivered by facsimile or by email in
the portable document format (PDF) or any other electronic format shall be accepted and binding as original signatures.

 

Section
11.9  Severability. Should any provision of this Agreement or the application thereof
to any Person or circumstance be held invalid or unenforceable to any extent: (a) such provision shall be ineffective to the extent,
and only to the extent, of such unenforceability or prohibition and shall be enforced to the greatest extent permitted by Law,
(b) such unenforceability or prohibition in any jurisdiction shall not invalidate or render unenforceable such provision as applied
(i) to other Persons or circumstances or (ii) in any other jurisdiction, and (c) such unenforceability or prohibition shall not
affect or invalidate any other provision of this Agreement.

 

Section
11.10 Time is of the Essence. Each of the Parties hereby expressly acknowledge and agree that time is of
the essence for each and every provision of this Agreement.

 

Section
11.11 No Third-Party Beneficiaries. Except as otherwise expressly provided in this Agreement, no Person
which is not a party shall have any right or obligation pursuant to this Agreement.

 

Section
11.12 No Strict Construction. Each of the Parties acknowledges that this Agreement has been prepared jointly
by the Parties, and shall not be strictly construed against either Party.

 

Section
11.13 No Set Off. Except as otherwise expressly provided in this Agreement, any payments required to be
made by any Party pursuant to this Agreement shall be made without any withholding, deduction or set-off, and no Party shall assert
a right of set-off with respect to any such payments at common law or otherwise.

 

    52

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
 BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE
 THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

    

 

Section
11.14 Acknowledgement by Buyer. Buyer acknowledges and agrees that it has conducted its own independent
review and analysis of, and, based thereon, has formed an independent judgment concerning, the Company and the prospects of the
Transferred Business. In entering into this Agreement, Buyer has relied solely upon its own investigation and analysis, and Buyer:

 

(a)
acknowledges that, other than as set forth in this Agreement, the Schedules hereto and the certificates delivered pursuant hereto,
neither Seller, the Company, their respective Affiliates, nor any of their respective Representatives makes or has made any representation
or warranty, either express or implied, including with respect to (i) the accuracy or completeness of any of the information provided
or made available to Buyer or its Representatives prior to the execution of this Agreement, or (ii) any projections, forecasts,
estimates, plans or budgets of future revenues, expenses or expenditures, future results of operations (or any component thereof),
future cash flows (or any component thereof) or future financial condition (or any component thereof) of the Company or the Transferred
Business;

 

(b)
agrees, to the fullest extent permitted by Law (except with respect to claims of fraud), that none of Seller, the Company their
respective Affiliates, or any of their respective equityholders or Representatives shall have any personal liability or responsibility
whatsoever to Buyer on any basis (including contract, tort, or otherwise) based upon any information provided or made available,
or statements made, to Buyer prior to the execution of this Agreement;

 

(c)
acknowledges that it is not aware of any facts or circumstances concerning Seller, the Company or their respective Affiliates
which could result in any representation, warranty or covenant contained herein being untrue or inaccurate in any respect;

 

(d)
acknowledges that the representations and warranties of the Company set forth in Article III do not address the
BCMA CAR-T Program, the CAR-NK Program or the CTL Program, and the BCMA CAR-T Program, the CAR-NK Program and the CTL Program
shall be excluded from Buyer’s consideration when evaluating the representations and warranties of the Company in Article
III; and

 

(e)
acknowledges that each of Seller and the Company make no representations or warranties of any kind or nature, express or implied,
as to the condition, value, quality or prospects of the Company, other than as expressly set forth in Articles III
and IV.

 

Section
11.15 No Additional Representations. Other than as set forth in Articles III and IV,
each of Seller and the Company expressly disclaims any representations or warranties of any kind or nature, express or implied,
as to the condition, value, quality or prospects of the Company.

 

 

[Signature
page follows]

 

    53

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
 BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE
 THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

    

 

IN
WITNESS WHEREOF, the parties have executed this Agreement and Plan of Merger as of the date first written above.

 

	 	ANTHROGENESIS CORPORATION 
	 	 	 	 
	 	By:	/s/ Jonathan Biller
	 	 	Name:	 
	 	 	Title:	 
	 	 	 	 
	 	 	 	 
	 	CELGENE CORPORATION 
	 	 	 	 
	 	By:	/s/ Mark J. Alles
	 	 	Name:	Mark J. Alles
	 	 	Title:	Chief Executive Officer
	 	 	 	 
	 	 	 	 
	 	CELULARITY INC.
	 	 	 	 
	 	By:	/s/ Robert J. Hariri
	 	 	Name:	Robert J. Hariri
	 	 	Title:	Chief Executive Officer
	 	 	 	 
	 	 	 	 
	 	CLARITY ACQUISITION CORP
	 	 	 	 
	 	By:	/s/ Robert J. Hariri
	 	 	Name:	Robert J. Hariri
	 	 	Title:	President
	 	 	 	 
	 	 	 	 
	 	CLARITY ACQUISITION II LLC
	 	 	 	 
	 	By:	/s/ Robert J. Hariri
	 	 	Name:	Robert J. Hariri
	 	 	Title:	President

 

 

[Signature
Page to Agreement and Plan of Merger]

 

    54Exhibit
10.24

 

CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED

BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE

THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

 

Execution Version

 

 

 

 

 

CONTINGENT VALUE RIGHTS AGREEMENT

by and between

CELULARITY INC.

and

the HOLDERS

 

 

Dated: August 15, 2017

 

 

 

 

 

     

    CERTAIN
                                         CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED 

                                         BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE 

                                         THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

    

 

Table
of Contents

 

	 	 	 	Page
	 	 	 	 
	Article I DEFINITIONS	 	2
	 	Section 1.1	Definitions	 	2
	 	Section 1.2	Interpretation and Rules of Construction	 	4
	Article II CONTINGENT VALUE RIGHTS	 	5
	 	Section 2.1	CVRs	 	5
	 	Section 2.2	Transfer of CVRs	 	5
	 	Section 2.3	No Certificate; Registration; Registration of Transfer; Change of Address	 	6
	 	Section 2.4	Payment Procedures	 	6
	 	Section 2.5	No Voting, Dividends or Interest; No Equity or Ownership Interest	 	10
	 	Section 2.6	Company Programs; Accounting Records	 	10
	Article III MISCELLANEOUS	 	11
	 	Section 3.1	Notices	 	11
	 	Section 3.2	Entire Agreement	 	12
	 	Section 3.3	Successors and Assigns	 	12
	 	Section 3.4	Consent to Amendments; Waiver	 	12
	 	Section 3.5	No Third-Party Beneficiaries	 	12
	 	Section 3.6	Governing Law; Service of Process; Venue	 	12
	 	Section 3.7	Further Assurances	 	13
	 	Section 3.8	Severability	 	13
	 	Section 3.9	Counterparts	 	13
	 	Section 3.10	No Set Off	 	13
	 	Section 3.11	Time is of the Essence	 	13
	 	Section 3.12	No Strict Construction	 	13
	 	Section 3.13	Authorization of the Holders’ Representative	 	14
	 	Section 3.14	Tax Treatment	 	15

 

    i

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED 
 BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE 
 THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

    

 

CONTINGENT VALUE RIGHTS AGREEMENT

 

THIS CONTINGENT VALUE
RIGHTS AGREEMENT, dated as of August 15, 2017 (this “Agreement”), is entered into by and between Celularity
Inc., a Delaware corporation (“Buyer”) and the Holders (as defined below).

 

RECITALS

 

WHEREAS, Buyer, Anthrogenisis
Corp., a New Jersey corporation (the “Company”), Celgene Corporation, a Delaware corporation (“Celgene”),
Clarity Acquisition Corp., a New Jersey corporation and a wholly owned subsidiary of Buyer, and Clarity Acquisition II LLC, a New
Jersey limited liability company and a wholly owned subsidiary of Buyer, have entered into an Agreement and Plan of Merger, dated
as of July 1, 2017 (as it may be amended, modified or supplemented from time to time, the “Merger Agreement”),
pursuant to which (a) Merger Sub 1 will be merged with and into the Company, with the Company continuing as the surviving entity
(“Merger One”) and (b) immediately following the consummation of Merger One, the Company will be merged
with and into Merger Sub 2, with Merger Sub 2 continuing as the surviving entity (“Merger Two” and together
with Merger One, the “Mergers”);

 

WHEREAS, pursuant to
the Merger Agreement, and in accordance with the terms and conditions thereof, Buyer has agreed to provide to Celgene the right
to receive contingent distributions from the Buyer (a) upon the achievement of certain regulatory and commercial milestones and
(b) in the form of contingent distributions based on Net Sales (as defined below), in each case, as hereinafter described in accordance
with the terms hereof and of the Merger Agreement;

 

WHEREAS, in connection
therewith, as part of the Merger Consideration to be paid by Buyer in respect of the Mergers, one (1) CVR (as defined below) is
hereby being issued by Buyer in respect of each Buyer Share (as defined in the Merger Agreement) to the holder thereof, which CVR
will be inseparable from the related Buyer Share except as otherwise provided pursuant to Section 2.2; and

 

WHEREAS, the parties
hereto have done all things necessary to make the CVRs, when issued pursuant to the Merger Agreement and hereunder, the valid obligations
of Buyer and to make this Agreement a valid and binding agreement of Buyer, in accordance with its terms.

 

NOW, THEREFORE, in
consideration of the premises and the consummation of the transactions referred to above, and for other good and valuable consideration,
the receipt and sufficiency of which is hereby acknowledged, it is mutually covenanted and agreed, for the proportionate benefit
of all Holders (as defined below), as follows:

 

     

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED 
 BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE 
 THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

    

 

Article
I

DEFINITIONS

 

Section
1.1 Definitions. Capitalized terms used
but not otherwise defined herein shall have the meanings ascribed thereto in the Merger Agreement. The following terms shall
have the meanings ascribed to them as follows:

 

“Agreement”
has the meaning set forth in the Preamble.

 

“Annual
Net Sales” means, [***].

 

“Celgene”
has the meaning set forth in the Recitals.

 

“Commercial
Milestone” has the meaning set forth in Section 2.4(d)(i).

 

“Commercial
Milestone Distributions” means, collectively, the First Commercial Milestone Distributions, the Second Commercial
Milestone Distributions and the Third Commercial Milestone Distributions.

 

“Commercial
Milestone Report” has the meaning set forth in Section 2.4(d)(i).

 

“Commercially
Reasonable Efforts” means, with respect to Buyer’s and its Affiliates’ obligations under this Agreement
to undertake research, Development, Manufacturing or Commercialization activities, as applicable, the [***] Develop and Commercialize
[***] the research, Development, Manufacturing or Commercialization of a similarly situated compound or product at a similar stage
of Development or Commercialization as the applicable Company Program Product, (a) taking into account issues of safety, efficacy,
product profile, the competitiveness of the marketplace, the proprietary position of the Company Programs, the regulatory structure
involved, profitability of the Company Programs and other relevant commercial factors, and (b) without taking into account any
other product, compound, or asset that is Developed, Commercialized, or Controlled by Buyer or its Affiliates.

 

“Company”
has the meaning set forth in the Recitals.

 

“CVR”
has the meaning set forth in Section 2.1.

 

“CVR Register”
has the meaning set forth in Section 2.3(b).

 

“Disputed
Amounts” has the meaning set forth in Section 2.4(d)(v).

 

“First
Commercial Milestone Distribution” means an amount equal to $[***] divided by the total number of CVRs
without interest thereon.

 

“First
Commercial Sale” means the first commercial sale in a given country of a Company Program Product by Buyer, the Company
or any of their respective Affiliates, distributors, licensees or agents to a third party in an arms’ length transaction
following receipt of applicable Regulatory Approval of such Company Program Product in such country. Sales for test marketing or
clinical trial purposes shall not constitute a First Commercial Sale.

 

    2

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED 
 BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE 
 THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

    

 

“GAAP”
means United States generally accepted accounting principles as in effect from time to time, provided that, to the extent that
a Party adopts International Financial Reporting Standards (“IFRS”), then “GAAP”
means IFRS, consistently applied.

 

“Holder”
means, at the relevant time, a Person in whose name a CVR is registered in the CVR Register and who has executed this Agreement
or a joinder hereto.

 

“Holders’
Representative” has the meaning set forth in Section 3.13(a).

 

“Independent
Accountant” has the meaning set forth in Section 2.4(d)(v).

 

“IPO”
means the first firm commitment underwritten public offering of securities of Buyer pursuant to an effective registration statement
under the Securities Act of 1933, as amended (other than a registration statement relating to the sale of securities to employees
of Buyer pursuant to a stock option, stock purchase or similar plan or an SEC Rule 145 transaction).

 

“Marketing
Exclusivity” means, with respect to a Company Program Product and a particular country, that the Company Program
Product has been granted marketing exclusivity by a Regulatory Authority, whereby the Regulatory Authority has neither reviewed
nor approved a marketing authorization application or similar regulatory submission submitted by a Person other than the Company,
its Affiliates or licensees for another product containing the same active pharmaceutical ingredient as that which is contained
in such Company Program Product.

 

“Merger
Agreement” has the meaning set forth in the Recitals.

 

“Merger
One” has the meaning set forth in the Recitals.

 

“Merger
Two” has the meaning set forth in the Recitals.

 

“Mergers”
has the meaning set forth in the Recitals.

 

“Milestone
Distributions” means the Regulatory Milestone Distributions and the Commercial Milestone Distributions.

 

“Net Sales”
means [***].

 

“Quarterly
Progress Report” has the meaning set forth in Section 2.6(b).

 

“Regulatory
Milestone Distribution” means an amount equal to $[***] divided by the total number of CVRs, without interest
thereon.

 

“Review
Period” has the meaning set forth in Section 2.4(d)(iii).

 

    3

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED 
 BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE 
 THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

    

 

“Sale of
Buyer” shall mean: (a) a consolidation or merger of Buyer which results in the stockholders of Buyer immediately
prior to the transaction owning less than a majority of the equity or voting power of the surviving entity, (b) the sale, transfer
or lease of all or substantially all of Buyer’s assets, (c) the grant of an exclusive license to all or substantially all
of Buyer’s intellectual property that is used to generate all or substantially all of Buyer’s revenues, (d) any sale
of all or substantially all of Buyer’s equity or any other transaction which results in the stockholders of Buyer immediately
prior to the transaction owning less than a majority of the equity or voting power of the surviving entity but not including any
transaction or series of transactions principally for bona fide equity financing purposes in which cash is received by Buyer or
indebtedness of Buyer is cancelled or converted (or a combination thereof), or (e) a liquidation, dissolution or winding up of
Buyer.

 

“Second
Commercial Milestone Distribution” means an amount equal to $[***] divided by the total number of CVRs, without
interest thereon.

 

“Statement
of Objections” has the meaning set forth in Section 2.4(d)(iv).

 

“Statements”
has the meaning set forth in Section 2.4(c)(ii).

 

“Third
Commercial Milestone Distribution” means an amount equal to $[***] divided by the total number of CVRs, without
interest thereon.

 

“Variable
Distribution” means, for a given calendar year and Company Program, an amount per CVR equal to [***] of the Annual
Net Sales for such Company Program divided by the total number of CVRs, without interest thereon.

 

“Variable
Distribution Report” has the meaning set forth in Section 2.4(d)(ii).

 

“Variable
Distribution Term” has the meaning set forth in Section 2.4(c)(i).

 

Section
1.2 Interpretation and Rules of Construction. Unless otherwise indicated to the contrary herein by the context or use
thereof:

 

(a)
a capitalized term has the meaning assigned to it;

 

(b)
when a reference is made in this Agreement to an Article or Section, such reference is to an Article or Section of this
Agreement;

 

(c)
the table of contents and headings for this Agreement are for reference purposes only and do not affect in any way the
meaning or interpretation of this Agreement;

 

(d)
the words, “herein,” “hereto,” “hereof” and words of similar import refer to this
Agreement as a whole and not to any particular Section or paragraph hereof;

 

(e)
references to “including” in this Agreement shall mean “including, without limitation,” whether or
not so specified;

 

(f)
references in the singular or to “him,” “her,” “it,” “itself,” or other like
references, and references in the plural or the feminine or masculine reference, as the case may be, shall also, when the
context so requires, be deemed to include the plural or singular, or the masculine or feminine reference, as the case may
be;

 

    4

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED 
 BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE 
 THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

    

 

(g)
references to any statute shall be deemed to refer to such statute as amended from time to time and to any rules or
regulations promulgated thereunder;

 

(h)
all accounting terms used herein and not expressly defined herein shall have the meanings assigned to such terms in
accordance with GAAP;

 

(i)
all terms defined in this Agreement have the defined meanings when used in any certificate or other document made or
delivered pursuant hereto, unless otherwise defined therein; and

 

(j)
all references to “$” will be references to United States Dollars, and with respect to any Contract, obligation,
liability, claim or document that is contemplated by this Agreement, but denominated in currency other than United States
Dollars, the amounts described in such Contract, obligation, liability, claim or document will be deemed to be converted into
United States Dollars for purposes of this Agreement based on the noon buying rate in New York, as certified weekly by the
Federal Reserve Bank of New York, in effect as of the applicable date of determination.

 

Article
II

CONTINGENT VALUE RIGHTS

 

Section
2.1 CVRs. Pursuant to the terms of the Merger Agreement, Buyer is hereby issuing one (1) contractual contingent value
right (each, a “CVR”) in respect of each Buyer Share to the holder thereof; provided, however,
that in the event of a recapitalization, reclassification of the Buyer Shares, stock split, reverse stock split, division or
subdivision of the Buyer Shares, consolidation of the Buyer Shares or similar transaction, the number of outstanding CVRs
shall be appropriately adjusted so there remains one (1) CVR in respect of each Buyer Share then outstanding. Other than as
set forth in the immediately preceding sentence, Buyer shall not issue any CVRs.

 

Section
2.2 Transfer of CVRs. CVRs may not be sold, assigned, transferred, pledged, encumbered or disposed of in any manner,
in whole or in part, other than in connection with the sale, assignment, transfer, pledge encumbrance or disposition of the Buyer
Shares to which such CVRs relate; provided, however, that upon an IPO or a Sale of Buyer, each CVR shall become separated from
the related Buyer Share and may be sold, assigned, transferred, pledged, encumbered or disposed of by the Holder thereof. Any
attempted sale, assignment, transfer, pledge, encumbrance or disposition of CVRs, in whole or in part, in violation of this Section
2.2 shall be void ab initio and of no effect.

 

    5

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED 
 BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE 
 THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

    

 

Section
2.3 No Certificate; Registration; Registration of Transfer; Change of Address.

 

(a)
CVRs shall not be evidenced by a certificate or other instrument.

 

(b)
Buyer shall keep a register (the “CVR Register”) for the purposes of (i) identifying the Holders of
CVRs and maintaining each such Holder’s address and wire instructions, and (ii) registering CVRs and transfers
thereof.

 

(c)
Upon any transfer of CVRs, the registered Holder or Holders thereof shall notify Buyer of such transfer and, to the extent
the applicable transferee of the CVRs is not already a Holder, such notice shall be accompanied by (i) a joinder to this
Agreement duly executed by such transferee, and (ii) wire instructions and address for notices for such transferee. Upon
receipt of notice of transfer from a registered Holder or Holders of CVRs, Buyer shall register the transfer of the
applicable CVRs in the CVR Register. All duly transferred CVRs registered in the CVR Register shall be the valid obligations
of Buyer, evidencing the same right, and entitling the transferee to the same benefits and rights under this Agreement, as
those held by the transferor. Any transfer or assignment of CVRs shall be without charge (other than the cost of any transfer
tax or similar tax or charge) to the applicable Holder.

 

(d)
A Holder may make a written request to Buyer to change such Holder’s address or wire instructions of record in the CVR
Register. Such written request must be duly executed by such Holder. Upon receipt of such written request, Buyer shall
promptly record the change of address or wire instructions, as applicable, in the CVR Register.

 

Section
2.4 Payment Procedures.

 

(a) Regulatory
Milestone Distributions. With respect to each Company Program, following receipt of each of (i) [***], and (ii) [***],
Buyer shall make a distribution to each Holder an amount equal to the product of (x) the Regulatory Milestone Distribution,
and (y) the total number of CVRs held by such Holder. With respect to each such [***] and [***], Buyer shall or shall cause
the Company to, give the Holders’ Representative prompt written notice of receipt thereof and, in any event, within
[***]. If payable, the Regulatory Milestone Distributions shall be paid to the Holders within [***] after such notice of
[***] is given by Buyer or the Company to the Holders’ Representative, and in any event within [***] after the
Company’s [***]. Buyer shall pay to each Holder any such Regulatory Milestone Distributions by wire transfer of
immediately available funds to the account of record for such Holder in the CVR Register. For the avoidance of doubt, the
Regulatory Milestone Distributions in respect of [***] [***] and the Regulatory Milestone Distributions in respect of [***]
shall be due and payable only once with respect to each Company Program.

 

(b) Commercial
Milestone Distributions. With respect to each Company Program, upon the first achievement of Annual Net Sales for such
Company Program that equals or exceeds:

 

(i) [$***],
Buyer shall pay to each Holder an amount equal to the product of (x) the First Commercial Milestone Distribution, and (y) the
total number of CVRs held by such Holder;

 

    6

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED 
 BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE 
 THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

    

 

(ii)
[$***], Buyer shall pay to each Holder an amount equal to the product of (x) the Second Commercial Milestone Distribution, and
(y) the total number of CVRs held by such Holder;

 

(iii)
[$***], Buyer shall pay to each Holder an amount equal to the product of (x) the Third Commercial Milestone Distribution, and
(y) the total number of CVRs held by such Holder.

 

Each Commercial Milestone Distribution,
if payable, shall be paid within [***] after the first to occur of (x) the Holders’ Representative’s receipt from Buyer
of a Commercial Milestone Report indicating that such Commercial Milestone Distributions are due and payable to the Holders, or
(y) the final determination that such Commercial Milestone Distributions are payable in accordance with Section 2.4(d).
Buyer shall pay to each Holder any such Commercial Milestone Distributions by wire transfer of immediately available funds to the
account of record for such Holder in the CVR Register. For the avoidance of doubt, each of the First Commercial Milestone Distributions,
the Second Commercial Milestone Distributions and the Third Commercial Milestone Distributions shall be due and payable only once
for each Company Program.

 

(c) Variable
Distributions.

 

(i)
With respect to each Company Program and calendar year, Buyer shall pay to each Holder an amount equal to the product of (x) the
applicable Variable Distribution, and (y) the total number of CVRs held by such Holder. Variable Distributions payable under this
Section 2.4(c) shall be paid by Buyer on a Company Program Product-by-Company Program Product basis from the date of the First
Commercial Sale of any Company Program Product in a particular country, until the latest to occur of (i) the expiration of the
last to expire of any Valid Claim of a Company Patent Covering such Company Program Product in such country, (ii) expiration of
Marketing Exclusivity with respect to such Company Program Product in such country, or (iii) the tenth (10th) anniversary of the
Closing Date (each such term with respect to a Company Program Product, a “Variable Distribution Term”).

 

(ii)
Variable Distributions shall be made by wire transfer of immediately available funds to the account of record for each Holder
in the CVR Register within [***] after Buyer delivers to the Holders’ Representative a Statement indicating that such Variable
Distributions are due and payable to the Holders, and in any event within [***] after the end of the calendar quarter with respect
to which such Variable Distributions were earned.

  

(d) Reports.

 

(i)
Within [***] after the end of each calendar quarter, commencing with the calendar quarter during which the First Commercial Sale
occurs and ending with the [***] consecutive calendar quarter during which there have been no Net Sales whatsoever, Buyer shall
prepare and deliver to the Holders’ Representative a written report in which Buyer certifies, with respect to each Company
Program, the Annual Net Sales therefor as of the end of such calendar quarter, whether any Annual Net Sales level described in
Section 2.4(b)(i), (ii) or (iii) (each, a “Commercial Milestone”)
has occurred as of the end of such calendar quarter and, if so, the Commercial Milestone Distribution(s) due to the Holders (each,
a “Commercial Milestone Report”). For clarity, in each Commercial Milestone Report, Buyer shall certify
as to the occurrence of the Commercial Milestone, whether Buyer, its Affiliate, licensee, assignee or successor in interest achieved
the Commercial Milestone.

 

    7

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED 
 BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE 
 THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

    

 

(ii) Within
[***] after the end of each calendar quarter, commencing with the calendar quarter during which the First Commercial Sale
occurs and ending with the calendar quarter during which the last to expire Variable Distribution Term has expired, Buyer
shall prepare and deliver to the Holders’ Representative a statement setting forth Buyer’s good faith calculation
of (i) Net Sales on a country-by-country and Company Program Product-by-Company Program Product basis for such calendar
quarter, including, in reasonable detail, the deductions from gross sales used to calculate such Net Sales, and (ii) the
resulting Variable Distributions, if any, to be paid to the Holders hereunder in respect of such calendar quarter (each, a
“Variable Distribution Report” and, together with the Commercial Milestone Reports, the
“Statements”). Each Variable Distribution Report shall be prepared by Buyer in accordance with
GAAP. Within [***] after delivery to the Holders’ Representative of a Variable Distribution Report indicating that any
Variable Distribution(s) are due to the Holders, Buyer shall pay to the Holders, by wire transfer of immediately available
funds to the account of record for each Holder in the CVR Register, such Variable Distribution(s).

 

(iii)
After receipt of a Statement, the Holders’ Representative shall have [***] (the “Review
Period”) to review such Statement. During the Review Period, the Holders’ Representative and its
accountants shall have reasonable access to the books and records of Buyer, the Company and any of their respective
Affiliates, the personnel of, and work papers prepared by, Buyer, the Company or their accountants to the extent that they
relate to the applicable Statement and to such historical financial information relating to the Statement as the
Holders’ Representative may reasonably request for the purpose of reviewing the applicable Statement and to prepare a
Statement of Objections (as defined below), provided, that such access shall be in a manner that does not materially
interfere with the normal business operations of Buyer or the Company. For the avoidance of doubt, each Company Program
Product shall be included in only one Company Program for purposes of this Agreement.

 

(iv)
On or prior to [the last day] of the applicable Review Period, the Holders’ Representative may object to the applicable
Statement by delivering to Buyer a written statement setting forth the Holders’ Representative objections in reasonable
detail, indicating each disputed item or amount and the basis for the Holders’ Representative’s disagreement
therewith (the “Statement of Objections”). If the Holders’ Representative delivers a
Statement of Objections before [***], Buyer and the Holders’ Representative shall negotiate in good faith to resolve
such objections within [***] after the delivery of the Statement of Objections and, if the same are so resolved within such
[***] period, the applicable Statement, with such changes as may have been previously agreed in writing by Buyer and the
Holders’ Representative, if any, shall be final and binding on the parties. The failure of the Holders’
Representative to object to any Statement pursuant to this Section 2.4(d)(iv) shall not prejudice in any
respect the Holders’ Representative’s rights under Section 2.4(d)(vii).

 

    8

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED 
 BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE 
 THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

    

 

(v) If
Buyer and the Holders’ Representative fail to reach an agreement with respect to all of the matters set forth in a
Statement of Objections before expiration of the applicable [***] period, then any amounts remaining in dispute
(“Disputed Amounts”) shall be submitted for resolution to the office of a mutually agreed,
impartial, nationally recognized firm of independent certified public accountants (the “Independent
Accountant”) who, acting as experts and not arbitrators, shall resolve the Disputed Amounts only and make any
adjustments to the applicable Statement and the applicable calculations set forth therein. The Independent Accountant shall
only decide the specific items under dispute by the parties and their decision for each Disputed Amount must be within the
range of values assigned to each such item in the applicable Statement and Statement of Objections, respectively. The
Independent Accountant shall make a determination as soon as practicable within [***] after its engagement (or such other
time as the parties shall agree in writing), and their resolution of the Disputed Amounts and their adjustments to the
applicable Statement and the applicable calculations set forth therein shall be conclusive and binding upon the parties. The
fees and expenses of the Independent Accountant(s) shall be paid [***.]

 

(vi)
Within [***] following final determination that any Commercial Milestone Distributions are due and owing to the Holders in
accordance with this Section 2.4, to the extent such Commercial Milestone Distributions have not already been
paid to the Holders, Buyer shall pay to the Holders, by wire transfer of immediately available funds to the account of record
for each Holder in the CVR Register, such Commercial Milestone Distributions. Within [***] following final determination of
the amount of any Variable Distributions to be paid to the Holders in respect of any calendar quarter in accordance with this Section
2.4, to the extent such amount is greater than the Variable Distributions actually paid by the Company to the Holders
in respect of such calendar quarter, Buyer shall pay to the Holders, by wire transfer of immediately available funds to the
account of record for each Holder in the CVR Register, such excess.

 

(vii)
Upon reasonable prior written notice to Buyer, Buyer shall, and shall cause the Company to, provide the Holders’
Representative and its accountants with access to examine all of the books and records of the Company as may be reasonably
necessary or useful for the purpose of conducting a review or audit of the calculations of Net Sales and Annual Net Sales and
all Milestone Distributions and Variable Distributions payable under this Agreement. Such access shall be made available: (A)
during normal business hours; (B) in a manner reasonably designed to facilitate the Holders’ Representative’s
review or audit without unreasonable disruption to the Company’s business; and (C) no more than [***] each calendar
year until [***] [***]. Buyer shall promptly pay to the Holders the amount of any underpayment determined by the review or
audit plus interest at a rate of [***] on such amount accruing from the date of the underpayment to the date of payment of
such amount. If the review or audit determines that the Company has underpaid any Variable Distribution or Milestone
Distribution by [***] or more, then Buyer shall in addition, promptly pay the costs and expenses of the Holders’
Representative and its accountants in connection with such review or audit. The Statements and any and all records of the
Company examined by the Holders’ Representative and its accountants pursuant to this Section 2.4(d)(vii) shall
be deemed to be the confidential information of Buyer, the treatment of which shall be governed by Section 11.1 of the Merger
Agreement, mutatis mutandis, and Buyer may require that the Holders’ Representative and such accountants enter
into a reasonable confidentiality agreement restricting the use or disclosure of such confidential information.

 

    9

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED 
 BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE 
 THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

    

 

(e) Withholdings.
Buyer shall be entitled to withhold and deduct from any consideration payable or otherwise deliverable pursuant to this
Agreement such amounts as the Buyer is required to deduct and withhold therefrom under the Internal Revenue Code of 1986, as
amended, or any provision of state, local, or non-U.S. tax law. Buyer shall timely deduct, withhold, and pay over any
deducted or withheld amounts to the appropriate governmental entity and any such amounts that are so deducted or withheld and
paid over to the appropriate governmental entity shall be treated for all purposes of this Agreement as having been paid to
the person to whom such amounts would otherwise have been paid.

 

Section
2.5 No Voting, Dividends or Interest; No
Equity or Ownership Interest. CVRs shall not have any voting or dividend rights, and, except as set forth in this
Agreement, interest shall not accrue on any amounts payable in respect of CVRs.

 

Section
2.6 Company Programs; Accounting
Records.

 

(a)
From and after the Closing, and at Buyer’s sole cost and expense, Buyer shall use Commercially Reasonable Efforts to
Develop and Commercialize the Company Program Products in order to Commercialize Company Program Products in all
prophylactic, therapeutic and diagnostic uses throughout the world.

 

(b) On
the first Business Day of each calendar quarter occurring after the Closing Date, Buyer shall submit to the Holders’
Representative a written report covering Buyer’s, its Affiliate’s, licensees’ and/or assignees, as
applicable, progress in: (i) development and testing of all Company Program Products; (ii) preparing, filing, and obtaining
and
 maintaining of any Regulatory Approvals; and (iii) plans for the upcoming year related to commercializing the Company
Program Product(s) (each, a “Quarterly Progress Report”). Each such Quarterly Progress Report shall
contain reasonable detail so as to permit the Holders’ Representative to determine whether Buyer is meeting its
obligations pursuant to Section 2.6(a).

 

(c) From
and after the Closing Date until the end of the last to expire Variable Distribution Term, Buyer shall maintain distinct
accounting records for the Company.

 

    10

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED 
 BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE 
 THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

    

 

Article
III

MISCELLANEOUS

 

Section
3.1 Notices. All notices and other
communications given or made pursuant hereto shall be in writing and shall be deemed to have been duly given or made (a) as
of the date delivered, if delivered personally, prior to 5:00 p.m. local time, (b) on the date the delivering party receives
confirmation, if delivered by facsimile or electronic transmission, prior to 5:00 p.m. local time, (c) three (3) Business
Days after being mailed by registered or certified mail (postage prepaid, return receipt requested) or (d) one (1) Business
Day after being sent by overnight courier (providing proof of delivery), to the parties at the following addresses (or at
such other address for a party as shall be specified in a notice given in accordance with this Section
3.1):

 

If to Buyer to:

 

Celularity Inc.

7 Powder Horn Drive

Warren, New Jersey 07059

Telephone No.: [([***]]

Email: [***]

Attention: [***]

 

with a copy, which shall
not constitute notice to Buyer, to:

 

Jones Day

4655 Executive Drive, Suite 1500

San Diego, CA 92121

Facsimile: [***]

Attention: [***].

 

If to Celgene, so long as
it is the Holders’ Representative, to:

 

c/o Celgene Corporation

86 Morris Avenue

Summit, New Jersey 07901

Facsimile: [***]

Attention: [***]

 

with copies, which shall
not constitute notice to Celgene, to:

 

Proskauer Rose LLP

Eleven Times Square

New York, New York 10036

Facsimile: [***]

Attention: [***]

 

    11

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED 
 BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE 
 THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

    

 

If to any successor
Holders’ Representative, to the address set forth for the Holders’ Representative in the CVR Register.

 

Section
3.2 Entire Agreement. This Agreement and
the Merger Agreement represent the entire understanding of parties with reference to the matters covered hereby, and this
Agreement supersedes any and all other oral or written agreements hereto made with respect to CVRs, except for the Merger
Agreement.

 

Section
3.3 Successors and Assigns. Except as
otherwise expressly provided in this Agreement, neither this Agreement nor any of the rights, interests or obligations
hereunder may be assigned by Buyer without the prior written consent of the Holders’ Representative. The assignment by
a Holder of this Agreement or any of the rights, interests or obligations hereunder shall be made in compliance with Sections
2.2 and 2.3. All covenants and agreements set forth herein by or on behalf of the parties hereto shall
bind and inure to the benefit of the respective successors and permitted assigns of the parties hereto, whether so expressed
or not.

 

Section
3.4 Consent to Amendments; Waiver. This
Agreement may be amended or modified, in each case upon the approval, in writing, executed by Buyer and the Holders’
Representative. Each party to this Agreement may: (a) extend the time for the performance of any of the obligations or other
acts of the other parties; (b) waive any inaccuracies in the representations and warranties of the other parties contained
herein or in any document delivered by the other party or parties pursuant hereto or (c) waive compliance with any of the
agreements of the other parties or conditions to such parties’ obligations contained herein. Any such extension or
waiver will be valid only if set forth in an instrument in writing signed by the party to be bound thereby.

 

Section
3.5 No Third-Party Beneficiaries. Except
as otherwise expressly provided in this Agreement, no Person which is not a party shall have any right or obligation pursuant
to this Agreement.

 

Section
3.6 Governing Law; Service of Process; Venue. THIS AGREEMENT WILL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE
DOMESTIC LAWS OF THE STATE OF DELAWARE FOR CONTRACTS ENTERED INTO AND TO BE PERFORMED IN SUCH STATE WITHOUT GIVING EFFECT TO
ANY CHOICE OR CONFLICT OF LAW PROVISION OR RULE (WHETHER OF THE STATE OF DELAWARE OR ANY OTHER JURISDICTION) THAT WOULD CAUSE
THE APPLICATION OF THE LAWS OF ANY JURISDICTION OTHER THAN THE STATE OF DELAWARE. EACH PARTY HERETO HEREBY SUBMITS TO THE
EXCLUSIVE JURISDICTION OF THE UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF NEW YORK AND OF ANY NEW YORK STATE
COURT SITTING IN NEW YORK, NEW YORK FOR PURPOSES OF ALL LEGAL PROCEEDINGS ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE
TRANSACTIONS CONTEMPLATED HEREBY AND AGREES THAT PROCESS SHALL BE SERVED UPON SUCH PARTY IN THE MANNER SET FORTH IN SECTION
3.1, AND THAT SERVICE IN SUCH MANNER SHALL CONSTITUTE VALID AND SUFFICIENT SERVICE OF PROCESS. EACH PARTY HERETO
IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY LAW, ANY OBJECTION WHICH IT MAY NOW OR HEREAFTER HAVE TO THE LAYING OF
THE VENUE OF ANY SUCH PROCEEDING BROUGHT IN SUCH A COURT AND ANY CLAIM THAT ANY SUCH PROCEEDING BROUGHT IN SUCH A COURT HAS
BEEN BROUGHT IN AN INCONVENIENT FORUM. EACH PARTY HERETO HEREBY IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY
LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.

 

    12

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED 
 BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE 
 THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

    

 

Section
3.7 Further Assurances. The
parties hereto agree (a) to furnish upon request to each other such further information, (b) to execute and deliver to each
other such other documents, and (c) to do such other acts and things, all as the other parties may reasonably request for the
purpose of carrying out the intent of this Agreement.

 

Section
3.8 Severability. Should any provision
of this Agreement or the application thereof to any Person or circumstance be held invalid or unenforceable to any extent:
(a) such provision shall be ineffective to the extent, and only to the extent, of such unenforceability or prohibition and
shall be enforced to the greatest extent permitted by Law, (b) such unenforceability or prohibition in any jurisdiction shall
not invalidate or render unenforceable such provision as applied (i) to other Persons or circumstances or (ii) in any other
jurisdiction, and (c) such unenforceability or prohibition shall not affect or invalidate any other provision of this
Agreement.

 

Section
3.9 Counterparts. This Agreement may be executed in counterparts, all of which taken together shall constitute one
agreement. For purposes of this Agreement, signatures delivered by facsimile or by email in the portable document format
(PDF) or any other electronic format shall be accepted and binding as original signatures.

 

Section
3.10 No Set Off. Except as otherwise
expressly provided in Section 2.4(e) and Section 3.13(f), any payments required to be made by any
party pursuant to this Agreement shall be made without any withholding, deduction or set-off, and no party shall assert a
right of set-off with respect to any such payments at common law or otherwise.

 

Section
3.11 Time is of the Essence. Each of
the parties hereby expressly acknowledge and agree that time is of the essence for each and every provision of this
Agreement.

 

Section
3.12 No Strict Construction. Each of the
parties acknowledges that this Agreement has been prepared jointly by the parties, and shall not be strictly construed
against either party.

 

    13

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED 
 BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE 
 THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

    

 

Section
3.13 Authorization of the Holders’
Representative.

 

(a) Each
Holder hereby designates and appoints, authorizes and empowers Celgene (and each successor as is appointed in accordance with Section
3.13(d)) (the “Holders’ Representative”) to perform all such acts, on behalf of each
Holder, as are required, authorized or contemplated by this Agreement and the transactions contemplated hereby, which will
include the power and authority to: (i) carry out the duties and take such actions contemplated by this Agreement and to be
performed by the Holders’ Representative; (ii) give and receive all notices, grant any consents or approvals, execute
and deliver any and all documents in connection with any determination or dispute of any Milestone Distributions or Variable
Distributions and settle any disputes arising under this Agreement (including any dispute with respect to payment of any
Milestone Distributions or Variable Distributions); and (iii) take all actions necessary or appropriate in the judgment of
the Holders’ Representative for the accomplishment of the foregoing to effectuate and carry out the terms and purposes
of the transactions contemplated by this Agreement.

 

(b)
Each Holder hereby acknowledges and agrees that the Holders’ Representative shall be the only Person authorized to take
any action so required, authorized or contemplated by this Agreement by any Holder and, without limiting the generality of
the foregoing, each Holder hereby acknowledges and agrees that Buyer shall be required to provide any notices to the Holders
pursuant to this Agreement solely to the Holders’ Representative. Each Holder further designates and appoints the
Holders’ Representative as his agent for service of process with respect to any disputes regarding or arising out of
this Agreement. Any action taken by the Holders’ Representative in the name of or on behalf of any Holder in connection
with any matter arising under this Agreement shall be binding upon such Holder and its successors, agents and heirs.

 

(c) The
grant of authority provided for in this Section 3.13: (i) is coupled with an interest and will be irrevocable
and survive the death, incompetency, bankruptcy or liquidation of any Holder and will be binding on any successor thereto;
and (ii) may be exercised by the Holders’ Representative acting by signing as the Holders’ Representative of any
Holder.

 

(d)
The Holders holding a majority in interest of the outstanding CVRs may remove and replace the Holders’ Representative
at any time upon notice to Buyer. Any references in this Agreement to the Holders’ Representative shall be deemed to
include any duly appointed successor Holders’ Representative. The Holders’ Representative may resign at any time
by providing written notice of its resignation to Buyer and the Holders holding a majority in interest of the outstanding
CVRs, which resignation shall be effective five (5) Business Days after the delivery of such notice or upon the earlier
appointment of a successor. If at any time there is not a Holders’ Representative, the Holder with the highest
percentage of the outstanding CVRs is entitled to serve as the Holders’ Representative until a successor is
appointed.

 

(e) Buyer
may conclusively and absolutely rely, without inquiry, and until the receipt of written notice of a change of the
Holders’ Representative, may continue to rely, without inquiry, upon the actions of the Holders’ Representative
as the actions of each Holder in all matters referred to in this Section 3.13.

 

(f) To
the extent that the Holders’ Representative incurs any reasonable, out-of-pocket costs and expenses in performing its
duties hereunder, it may instruct Buyer by written notice to, and Buyer shall (i) reduce its subsequent payment to the
Holders on a pro rata basis, based on the number of CVRs held by each such Holder, by an aggregate amount equal to the total
amount of such costs and expenses, and (ii) pay such aggregate amount to the Holders’ Representative.

 

    14

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED 
 BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE 
 THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

    

 

Section
3.14 Tax Treatment. The parties
acknowledge and agree that (i) except as otherwise provided pursuant to Section 2.2, each CVR is inseparable
from the related Buyer Share, and (ii) for U.S. federal income tax purposes, each such party intends that each CVR reflects
an equity or ownership interest in Buyer at the time of issuance and each CVR is part of, and represents a portion of the
rights and obligations of, the related Buyer Share. Except as otherwise required by applicable law, each of the parties
agrees to make all tax filings in a manner which is consistent with the intentions described in this Section
3.14.

 

 

[Remainder of the page left intentionally blank.]

 

    15

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED 
 BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE 
 THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

    

 

IN WITNESS WHEREOF,
each party hereto has caused this Agreement to be duly executed as of the date first written above by their respective officers
thereunto duly authorized.

 

	 	CELULARITY INC.
	 	 
	 	By:	/s/Robert Hariri
	 	 	Name:	Robert J. Hariri
	 	 	Title:	Chief Executive Officer

 

 

	 	CELGENE CORPORATION
	 	 
	 	By:	 
	 	 	Name:	 
	 	 	Title:	

 

[Signature Page to Contingent Value Rights Agreement]

 

    16

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED 
 BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE 
 THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

    

 

IN WITNESS WHEREOF,
each party hereto has caused this Agreement to be duly executed as of the date first written above by their respective officers
thereunto duly authorized.

 

	 	CELULARITY INC.
	 	 
	 	By:	 
	 	 	Name:	 
	 	 	Title:	
	 	 

 

	 	CELGENE CORPORATION
	 	 
	 	By:	/s/Jonathan Biller
	 	 	Name:	Jonathan Biller
	 	 	Title:	SVP, Tax & Treasury

 

 

[Signature
Page to Contingent Value Rights Agreement]

 

    17

     

    

  

Execution Version

 

Amendment
NO. 1 to THE

CONTINGENT VALUE RIGHTS agreement

 

This AMENDMENT NO.
1 TO THE CONTINGENT VALUE RIGHTS AGREEMENT (this “Amendment”) is entered into as of March 4, 2021,
by and between Celularity Inc., a Delaware corporation (the “Company”), and Celgene Corporation, a Delaware
corporation (“Celgene”).

 

WHEREAS, the Company
and Celgene are parties to that certain Contingent Value Rights Agreement, dated as of August 15, 2017 (the “Agreement”);

 

WHEREAS, pursuant
to Section 3.4 of the Agreement, any term of the Agreement may be amended or waived only upon the written consent of the Company
and Celgene, as the Holders’ Representative;

 

WHEREAS, the Company
and Celgene desire to amend the Agreement as set forth below; and

 

WHEREAS, capitalized
terms used but not defined herein shall have the meanings given to them in the Agreement.

 

NOW THEREFORE,
the Company and Celgene hereby agree as follows:

 

1. Amendment
to Section 2.2 (Transfer of CVRs). Section 2.2 of the Agreement is hereby amended and restated in its entirety to read as follows:

 

“Section
2.2. Transfer of CVRs.CVRs may not be sold, assigned, transferred, pledged, encumbered or disposed of in any manner,
in whole or in part, other than in connection with the sale, assignment, transfer, pledge, encumbrance or disposition of the Buyer
Shares to which such CVRs relate; provided, however, that upon the earliest to occur of (a) an IPO, (b) a Sale of
Buyer or (c) the Effective Time (as defined in that certain Merger Agreement and Plan of Reorganization, by and among GX Acquisition
Corp., a Delaware corporation, Alpha First Merger Sub, Inc., a Delaware corporation, Alpha Second Merger Sub, LLC, a Delaware limited
liability company and Buyer, dated as of January 8, 2021), each CVR shall become separated from the related Buyer Share and may
be sold, assigned, transferred, pledged, encumbered or disposed of by the Holder thereof. Any attempted sale, assignment, transfer,
pledge, encumbrance or disposition of CVRs, in whole or in part, in violation of this Section 2.2 shall be void ab
initio and of no effect.”

 

2. Continued
Validity of the Agreement. Except as specifically amended by this Amendment, the Agreement shall remain in full force and effect
as originally constituted.

 

3. Successors
and Assigns. Except as otherwise expressly provided in this Amendment, neither this Amendment nor any of the rights, interests
or obligations hereunder may be assigned by Buyer without the prior written consent of the Holders’ Representative. The assignment
by a Holder of this Amendment or any of the rights, interests or obligations hereunder shall be made in compliance with Sections
2.2 and 2.3 of the Agreement. All covenants and agreements set forth therein by or on behalf of the parties
thereto shall bind and inure to the benefit of the respective successors and permitted assigns of the parties thereto, whether
so expressed or not.

 

    

     

    

 

4. Governing
Law. This Amendment will be governed by and construed in accordance with the domestic laws of the state of Delaware for contracts
entered into and to be performed in such State without giving effect to any choice of conflict of law provision or rule (whether
of the State of Delaware or any other Jurisdiction) that would cause the application of the laws of any other jurisdiction other
than the State of Delaware. Each party hereto hereby submits to the exclusive jurisdiction of the United States District Court
for the Southern District of New York and of any New York State Court sitting in New York, New York for purposes of all legal proceedings
arising out of or relating to this Amendment or the transactions contemplated hereby and agrees that process shall be served upon
such party in the manner set forth in Section 3.1 of the Agreement, and that Service in such manner shall constitute
sufficient and valid service of process. Each party hereto irrevocably waives, to the fullest extent permitted by law, any objection
which it may now or hereafter have to the laying of the venue of any such proceeding brought in such a court and any claim that
any such proceeding brought in an inconvenient forum. Each party hereto hereby irrevocably waives any and all right to trial by
jury in any legal proceeding arising out of or relating to this Amendment or the transactions contemplated hereby.

 

5. Counterparts.
This Amendment may be executed in counterparts, all of which taken together shall constitute one agreement. For purposes of this
Amendment, signatures delivered by facsimile or by email in the portable document format (PDF) or any other electronic format shall
be accepted and binding as original signatures.

 

[Remainder of page intentionally left
blank.]

 

    2

     

    

 

IN WITNESS WHEREOF,
the parties have executed this Amendment as of the date first written above.

 

	 	CELULARITY INC.
	 	 
	 	By:	/s/ Robert J. Hariri, MD, PhD
	 	Name: 	Robert J. Hariri, MD, PhD
	 	Title: 	CEO

 

	 	CELGENE CORPORATION 
	 	 
	 	By:	/s/ Daniel O’Connell
	 	Name: 	Daniel O’Connell
	 	Title: 	Authorized Signatory

 

SIGNATURE PAGE TO AMENDMENT NO. 1

TO THE CONTINGENT VALUE RIGHTS AGREEMENT

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00325-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00325-of-00352.parquet"}]]